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ABSTRACT

Counsel for the medical software technologist faces an unusually complex, ongoing,
high-stakes challenge. Counsel operates in a special field of commercial, legal and
regulatory forces: (1) intellectual property laws which govern the expression and
protection of commercial rights derived from advances in medical science and
technology; (2) existing and proposed contracts/warranty laws that govern
technological commercial relationships; (3) negligence, professional liability, and
product liability laws that govern the marketing of medical technologies; and, (4) a
new body of regulation derived from the power of the federal government to indirectly
provide for the safety, effectiveness, privacy, and security of medical technologies
offered to the American public. Against that backdrop, the author provides an
illustration of the commercialization of a new medical software technology and
suggests a general approach to resolving the primary issues facing the medical
software technologist.
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"We are developing molecular imaging technology, which we will use to
image molecules within the body, within the cell."1 Elias Zerhouni
'A dirty little secret about 802.11b is that it can cover more than 20
kilometers with suitably directional antennas. Imagine reaching places
that do not have sufficient commercial value to justify classic
infrastructure.
In these cases, the viral nature of unlicensed
telecommunications becomes a major force of human development,
transforming everything from education to entertainment, hospitals to
hiring halls. ' 2 Nicholas Negroponte
'No one really knows how to run a secure enterprise network system. The
systems are fantastically complex, beyond human comprehension. In ten
years machines will be 1000 times more complex and 1000 times more
powerful. Privacy issues will loom more and more. Guidance will come
from law, social pressure, and ethics.' 3 Dan Farmer
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I Elias Zerhouni, Remarks Made During a National Public Radio "Science Friday" Broadcast
(September 20, 2002) available athttp://sciencefriday.com/pages/2002/Sep/hourl 092002.html.
2 Nicholas Negroponte, Being Wireless: Why Wi-Fi Lily Pads and Frogs Will Transform the
Future of Telecom, WIRED 118-19 (Oct. 2002); see also Nancy Gohring, Teeh 2002: Wi-Fi Blooms,
Wi-FiP Breakout Year, SEATTLE TIMES, Dec. 9, 2002, available at 2002 WL 3925102. Wi-Fi, also
known as WLAN or 801.11 technology, enables laptop computer users to wirelessly access the
Internet within the radius of an antenna hooked to a wireline Internet connection. Id.
3 Dan Farmer, Remarks Made Before the Internet Law & Policy Forum, "Security v. Privacy,"
(Sept. 18-19, 2002).
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INTRODUCTION
Over the past fifty years, the United States has mobilized its national technology
base, its communications structures, and its centralized regulatory and purchasing
power to develop strategically important, safe, effective, and highly reliable
information technology systems. For example, the United States Nuclear Regulatory
Agency regulates the software used to operate American nuclear power plants. 4 The
United States Department of Defense operates the world's most sophisticated and
secure digital networks. 5 The effort to advance the strategic interests of the United
States has led to the creation of standardized information technology practices and
techniques that are being adapted for use in the health care industry.
Scientists and entrepreneurs are striving to bring ultra- sophisticated medical
device software products to market. The coming generation of medical software will
provide incredibly detailed images of human tissues, compounds, and molecules. In
the very near future, health care facilities and medical practitioners will regularly
transmit three-dimensional digital maps of patient tissues, compounds, and
molecules over the wired and wireless Internet. 6 Since loss, alteration, corruption or
misuse of a portion of that data is inevitable, patient injury is also inevitable. Thus,
the legal responsibility for the loss, alteration, corruption, or misuse of patient data
will soon be a matter for the courts.
This article provides an overview of federal regulatory law, intellectual property
law, and negligence/products liability law that will govern the marketing of medical
device software in the United States. This article then suggests an approach to
address the primary business risks that holders of medical software intellectual

4
U.S.
Nuclear
Regulatory
Commission,
Computer
Codes,
available
at
http://www.nrc. gov/what-we- do/regulatory/research/comp- codes.html (last visited Apr. 15, 2003).
5 See Rear Admiral Kenneth D. Slaght, Remarks Before the Subcommittee on Research and
Development of the House Armed Services Committee on Navy Transformation (Feb. 20, 2002), at
http://chinfo.navy.mil/navpalib/testimony/research/kdslaght2O220.txt (describing how FORCEnet,
the Navy's transformational architecture linking Navy and Marine Corps and Allied and coalition
forces, will be integrated with the Department of Defense Global Information Grid).
6 See National Institute of Health, National Library of Medicine to Unveil Vast Potentialof
Internet2 for Improving Delivery of Health Care (Nov.
29,
2002),
available at
http://www.nih.gov/news/pr/nov2002/index.htm (last visited Apr. 15, 2003); IBM Life Sciences
Solutions, National DiritalMammography Archive: University of Pennsylvania Consortium and
IBM
Develop
Computing
Grid for
Breast
Cancer Screening
at
http://www3.ibm.com/software/success/cssdb.nsf/CS/DGUN-5B2Q35?.
For example,
a University
of
Pennsylvania consortium funded by grants from the National Science Foundation, the National
Library of Medicine, the National Institutes of Health, and Next Generation Internet are working
with IBM to develop the National Digital Mammography Archive (NDMA). Id. The effort, to be
completed in 2003, is to develop an Electronic Medical Record data grid and digital repository so
that the full range of a patient's healthcare files including high fidelity medical images (CT, MRI,
mammograms), records and clinical history could be stored an housed in networked data systems
allowing the management and fast retrieval of huge files; digital mammograms typically consume
160 Mb of storage per study per patient. Id.; see also Douglas Page, Universities PrepareNational
Digital
Mammography
Arelnve,
PACS
WEB,
at
http://www.diagnosticimaging.com/pacsweb/stories/news409OlOl.shtml (last visited Apr. 15, 2003);
National
Digital
Mammography
Archive,
Project
Overview,
at
http://nscpol.physics.upenn.edu/ndma/projovw.htm (last visited Apr. 15, 2003).
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property rights, medical software designers, businesses intent on marketing medical
device software, and businesses intent on marketing medical devices that integrate
or imbed medical software, will encounter in their business operations.

I. THE SETTING
You are fortunate to serve as counsel to a venture intent on marketing a longsought advance in medical device technology that employs software to analyze digital
representations of energy waves interacting with tissues, compounds and molecules
deep within the human body. The software can create patient tissue maps and
compare them with maps of known disease patterns, electronically store the data for
7
long-term use, and electronically transmit the data.
Your clients are a delight. As scientific-entrepreneurs, they are among the most
competent and dynamic individuals in society.8 As medical professionals they focus
their talents and research to improve the well being of mankind. As capitalists, they
encourage those with whom they deal to share in the risks and rewards: they offer
you founders' shares in the new venture in exchange for your counsel and continued
service.9
The new venture has invested large sums and thousands of hours developing the
new technology, creating and refining a strategic business plan for its
commercialization, and cultivating an intricate web of relationships with the
physicians, technologists, researchers, business executives, and venture capitalists to
market the new technology. 10
The venture's chief medical scientist believes the technology has the potential to
harness decades of painstaking research in a fundamentally new way. He states that
the technology could change the practice of medicine and improve untold numbers of
lives. He declares his intention to see the technology through delivery to the market.
The venture's lead software engineer matter-of-factly states that because of
accelerating advances in computing technology, the new integrated medical device
can be assembled from a mixture of technologies, old and new, including:

7 The Food and Drug Administration online Manufacturer and User Facility Device Experience
Database (MAUDE) includes a variety of entries disclosing the extent to which a number of
manufacturers are seeking FDA Pre-Market Approval to manufacture these types of devices.
s See Lisa Spefchman, Coleman's Bright Idea.* How One Scientists Took on 14 Major
Electronics Companies for Infringement and Won, AMERICAN LAWYER MEDIA'S LAw.COM
(September 9, 2002), athttp://www.law.com/index.shtml/ (last visited Apr. 15, 2003).
See Debra Baker, Who Wants to be a Millionaire. Law Firms Investing in Hot High-Tech
IPOs are Making a Fortune, but Some Critics Worry the Stock Craze is CloudingEthics Matters, 86
A.B.A.J. 36 (2000). In rosier days, Wilson Sonsini Goodrich & Rosati acquired 102,584 shares of VA
Linux, its client's stock, in exchange for legal services. Id. At the close of the first day of public
trading, the shares were valued at $24.5 million. Id.
10 See Paul A. Mathew, Entrepreneurship, Technology, and Law at the University of
Washington, CENTER FOR ADV. STUDY & RES. IN INTELL. PROP. NEWSL., Vol. 9, Issue I, (2002), at
http://www.law.washington.edu/Casrip/newsletter/newsv9ilMathew.pdf (last visited Apr. 15, 2003).
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*

Off-the-shelf "pulse emitters" and "pulse recorders" that record very
subtle changes in energy waves when the waves interact with human
tissue;

*

An off-the-shelf "converter" microprocessor that converts the signal
structures of the energy waves into electronic digital format;

* An

off-the-shelf "digitizer" that creates a three-dimensional depiction of

the tissues studied;
*

A new software program that analyzes the depictions of tissues for
minute fluctuations during the testing process;11

*

An off-the-shelf storage device that stores the depictions of tested
tissue and healthy tissue;

* An

off-the-shelf personal computer;

* An

off-the-shelf operating system;

* An

off-the-shelf communications program;

* An

off-the-shelf compression program; and

* An

off-the-shelf Internet communications program.

The venture's business executives enthusiastically detail the significant
commercial and diagnostic advantages the new integrated device offers: it can be
used to diagnose disease states far sooner then conventional technology; the use of
the technology produces few or no harmful side effects to patients or health care
professionals; the new equipment can be manufactured, distributed, serviced and
maintained at a fraction of the cost of existing equipment; and the performance of the
new equipment will improve as the new software is further refined and matures.
You suppress an inner shudder as your mind flashes through the events of the
past two years. As a result of the multi-trillion dollar "telecom" and "dot-gone"
financial debacles, the collapse of share prices of many leading technology companies,
the aftermath of "9-11," the revelation of widespread "Enron/Arthur Anderson"

11The scientific medical community has been working at fever pitch to create the scientific
standards and protocols necessary for the transfer of digitized medical imaging data. See generally

Marcela Hernandez-Hoyos et al., Computer-assisted Analysis of Th-ree-Dimensional Magnetic
Resonance Angiograms, RADIOGRAPHICS, 22:421-436 (2002); Usha Sinha & Hooshang Kangarloo,
Principal Component Analysis for Content-based Image Retrieval, RADIOGRAPHICS, 22:1271-1289
(2002); Bharti Temkin et al., Web-based Throee-dimensional Virtual Body Structures, J. AM. MED.
INFORMATICS. ASS'N, 9:425-436 (2002); Leo P. Lawler & Elliot K. Fishman, Multi-Detector Row
Computed Tomography of Thoracic Disease with Emphasis on 3D Volume Rendering and Computed
Tomography Angiography,RADIOGRAPHICS, 21:1257-1273 (2001).
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corporate accounting fraud, and new federal corporate laws, the venture capital
environment has been radically transformed.
As a result, venture capitalists (VC's) are requiring new technology ventures to
carry the economic and psychological baggage of the recent past. Venture capital
investment in new companies is only about 15% of what is was one year ago. Term
sheets are very difficult to come by, and valuations are extremely low. 12 For only the
second time in memory, VC's as a group recently returned more capital to their
13
investors than they obtained from them.
As a reflection of the maturation of the computer software industry, the mass
adoption of computing technology by the health care industry, 14 and the documented
risk of death or injury associated with the use of medical software, the Food and
Drug Administration (FDA) has put into place a new regulatory framework that
subjects medical device software to life-cycle scrutiny. Pursuant to Congressional
mandate, the United States Department of Health and Human Services (HHS) is in
the process of publishing regulations that will be used to govern the accessibility,
security, and privacy of "individually identifiable health care information."
Medical device tort liability is recognized throughout the United States. A
single "death case" now equates with ten-figure liability. Death and severe personal
injury arising from the malfunction of medical device software is a documented
reality.
Should the venture's new medical software obtain conditional FDA approval and
enter the health care market, the inevitable failure of the medical software will lead
the venture, the creator of the medical software program, the manufacturer of
associated medical devices, and the holder of the intellectual property rights in the
software program, to an encounter with the law of negligence and products liability.
There you stand, near the center of a high-risk, high-value, high-benefit
entrepreneurial endeavor. The new medical technology may improve the quality of
life for countless patients. Decades of scientific research will be subject to intense

12 See Tricia Duryee, VC Swoon Hurts Startups, SEATTLE TIMES, Oct. 29, 2002 available at
2002 WL 3919685. On a national scale, fewer companies received first round venture capital
investment in the third quarter than in any quarter in the past eight years. Id.; see also Tricia
Duryee, Venture CapitalistsReduce Stake in Washington Firms: 50 PercentDrop Seen From Last
Quarter SEATTLE TIMES, Oct. 26, 2002, available at 2002 WL 3919236; Luke Timmerman, Biotech'
On Edge as Money Evaporates:Local Firms Resort to Reserves, Layoffs, SEATTLE TIMES, Aug. 19,
2002, available at 2002 WL 3910238.
1"See Venture CapitalistGave More Than They Got in the 2nd Quarter,WALL ST. J., Aug. 6,
2002, availableat 2002 WL-WSJ 3402718.
14 See generallyJames S. Benson, Forces Reshaping the Performance and Contribution of the
US. Medical Device Industry, 51 FOOD DRUG COSM. L.J. 189 (1997); Dee Simmons, Medical Device
Software Regulation."An Industry Perspective, 51 FOOD DRUG COSM. L.J. 189 (1997). Leading
medical device manufacturers are marketing a variety of new medical imaging software of the type
contemplated by this article. See, e.g., GE Systems Medical, GE MedicalSystems Announces Latest
Molecular Medicine Initiatives,
News
Releases
(Nov.
6,
2002),
available
at
www.gemedicalsystems.com/company/pressroom/releases/prrelease_7622.html;
IBM,
Medical
Imaging Solutions, Innovative IT Infrastructure Solutions for the Next GenerationofMedicine, IBM
LIFE
SCIENCES
(December
3,
2002)
available
at
http://www3.ibm.com/solutions/lifesciences/solutions/medical.html.
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federal regulatory scrutiny. Academic standing and professional careers are on the
line. Staged investments in the tens of millions of dollars loom ahead.
Your clients ask whether you can help them structure operations of the venture
to reflect the venture's federal regulatory, intellectual property, and tort liability
concerns. Your advice, Counselor?

I. THE FEDERAL REGULATORY LANDSCAPE

A. Food and DrugAdministrationRegulation ofMedical Software
The FDA is broadly empowered to regulate the use of medical devices pursuant
to section 201(h) of the Federal Food, Drug, and Cosmetic Act. 15 A regulated
"medical device" is defined as:
[An instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or related article, including any component,
part or accessory, which is:
(1)recognized in the official National Formulary, or the
United States Pharmacopoeia, or any supplement to them;
(2) intended for use in the diagnosis of disease, or other
conditions, or in the cure, mitigation, treatment or prevention
of disease, in man;
(3) intended to affect the structure or any function of the
body of man . . .which does not achieve its primary intended
purposes through chemical action within or on the body of
man . . .and which is not dependent upon being metabolized
16
for the achievement of its primary intended purposes.
15See 21 U.S.C. § 321 (2000 & Supp. 2003). The FDA has comprehensive regulatory power
over a vast array of products sold in interstate commerce. Id. The FDA regulates biologics (safety of
the blood supply), cosmetics, drugs, electronic products (such as radiation safety performance
standards, diagnostic x-ray equipment, laser products, and ultrasonic therapy equipment), foods,
medical devices (involving pre-market approval of new devices, manufacturing and performance
standards, and tracking reports of device malfunctioning and serious adverse reactions), and
veterinary products. Id. The data base system that tracks the nation's blood supply is a regulated
"medical device". Id.
1621 U.S.C. § 321 (2000 & Supp. 2003). A disposable, wooden tongue depressor is a Class One
regulated "medical device." Id. at § 360(c). It is a simple device, involves low risk of harm to the
patient or the care giver, receives an administrative review of the labeling used to describe it, and
likely has no significant difference in technology or characteristics from other tongue depressors
used by the medical profession for the past 100 years. See id. The medical software device
envisioned in this article would probably be classified as a Class Three regulated "medical device."
See id. It would be a complex device that could present a high degree of risk to the patient were it to
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Pursuant to the Federal Food, Drug, and Cosmetic Act, any software product
meeting the definition of a "medical device" is subject to regulation by the FDA.17
The FDA regulates stand-alone software devices for which the software is not an
accessory to another device,18 any software accessory to a medical device that accepts
data and modifies it for input to a medical device, and any software that takes data
from a medical device and modifies if for presentation to the user. 19 Components,
20
parts, or accessories to a classified device are regulated like the parent device.
The FDA's new software regulatory framework is the result of two decades of
experience with the use of computer software in medical device technology. 21 The
policy has unfolded against a backdrop of the new Quality System Regulation for
medical devices, 22 and the enactment of the Food and Drug Administration
Modernization Act of 1997.23
The new FDA medical device software regulatory framework is based on the
following premises:
*

Software products meet the definition of medical devices and are
regulated as such, unless specifically exempted;

*

The FDA uses a risk-based approach to regulation;

*

The FDA will use the least amount of regulatory control necessary to
regulate risk;

provide incomplete or inaccurate diagnostic information. Additionally, the FDA has had little or no
experience with the safety and effectiveness of the device, and it would be subject to pre-market
approval and a comprehensive review by a team of experts. See generally Michael D. Green &
William B. Schultz, Tort Law Deference to FDA Regulation of Medical Devices, 88 GEO. L.J. 2119
(2000).
17 See E. Stewart Crumpler & Harvey Rudolph, FDA Software Policy and Regulation of
Medical Device Software, 52 FOOD DRUG COSM. L.J. 511, 512 (1997) (calling for comment on
prospective FDA computer software policy by senior FDA regulatory personnel).
18 Id. Regulated stand-alone medical software devices include pharmacy prescription ordering
systems, laboratory information management systems, blood establishment information
management systems and expert medical decision support systems. Id.
1) Id. Regulated accessory software devices include radiation treatment planning software,
digital imaging and image conversion software, picture archiving and communication systems, and
EEG and ECG waveform analysis software. Id.
20 Id. at 513.
21 Id. at 514-15. The first FDA medical software policy statement was issued in draft form in
1989. FDA Policy for Regulation of Computer Products, Draft, Food and Drug Administration,
Center for Devices and Radiological Health (1989), available at http://www.fda.gov/cdrh/ode/351.pdf
(last visited Apr. 15, 2003). The draft statement had no legal status, caused industry confusion, and
lead to the consumption of limited FDA resources in time consuming case-by-case determinations.
See Crumpler & Rudolph, supra note 17, at 514-15.
22 See 21 C.F.R. § 820.3 (1996).
23 Larry R. Pilot & Daniel R. Waldman, Food and Drug Administration Modernization Act of
1997."MedicalDevice Provisions,53 FOOD DRUG COSM. L. J. 267, 267-68 (1998).
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*

The FDA requires the use of design controls, independent audits, and
the identification of appropriate software standards;

*

Low-risk software devices have the least amount of control and will be
granted exemption
misbranding;

from

all regulatory

requirements

excepting

*

Moderate-risk software devices may qualify for less stringent 510(k)
"substantial equivalent" application review;

*

High-risk software devices shall be subject to very rigorous pre-market
24
approval review.

Three final FDA Guidance documents regulate medical devices that incorporate
or imbed medical software:
*

"Guidance for the Content of PreMarket Submissions for Software
Contained in Medical Devices;"25

*

"Off-the-Shelf Software Use in Medical Devices; ' 26

*

"General Principles of Software Validation; and Final Guidance for
' 27
Industry and FDA Staff.

1. Overview of "Guidancefor the Content ofPreMarketSubmissions for Software
Containedin MedicalDevices"
PreMarket Submissions provides a framework of software programming means
28
that must be used to obtain FDA approval to market medical device equipment.
PreMarket Submissions is applicable to all types of medical devices containing
software for which applicants file pre-market notifications (510(k)'s), Pre-market
Applications, Investigational Device Exemptions, and Humanitarian Device
24 See
25

Crumpler & Rudolph, supranote 17, at 514.
Center for Devices & Radiological Health, Guidance for FDA Reviewers and Industly

Guidance for the Content of Premarket Submissions for Software Containedin Medical Devices,
U.S. Food & Drug Administration (May 29, 1998), available at http://www.fda.gov/cdrh/ode/57.html

[hereinafter PremarketSubmissions].
26 Center for Devices & Radiological Health, Guidance for Industry, FDA Reviewers and
Compliance on Off-The-Shelf Software Use in Medical Devices, U.S. Food & Drug Administration
(August 17, 1998), available at http://www.fda.gov/cdrh/ode/guidance/585.html [hereinafter Off-TheShelf Software].
27 Center for Devices & Radiological Health, GeneralPrineiples of Software Validation, Final
Guidance for Industry and FDA Staff U.S. Food and Drug Administration (January 11, 2002),

available at http://www.fda.gov/cdrh/comp/guidance/938.html[hereinafter FinalGuidance].
28 PremarketSubmissions, supra note 25, at § 1.3.
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Exemptions. 29 Appendix B to PreMarket Submissions lists sixty-seven national and
international consensus standards, grouped by relevant class, that are to be viewed
as tools for achieving and demonstrating compliance with the FDA medical software
standard. 30 Appendix C contains an extensive bibliography of leading treatises and
3 1
guidance standards materials.
PreMarket Submissions uses the term "level of concern" to serve as a baseline
estimate of the severity of injury that a device could permit or inflict, directly or
indirectly, on a patient or operator because of a latent failure or design flaw
encountered during the medical use of medical device software. The extent of the
pre-market review process pertaining to software products is proportional to the level
of concern. Manufacturers are asked to specify the level of concern for the software
product and describe how the level of concern was determined. The level of concern
32
for medical device software varies over a continuum.
PreMarket Submissions requires that the severity of the hazard resulting from
the failure of the software be characterized assuming that software failure shall
occur. 33

Software failures are deemed to be systemic in nature; the probability of

their occurrence cannot be determined in advance using traditional statistical
methods.
PreMarket Submissions establishes three levels of concern: major, moderate or
minor. A major level of concern is present when failure of the software product could
result in incorrect or delayed information that could cause the death or serious injury
of the patient, the operator, or both. A moderate level of concern is present when
failure of the software product could result in incorrect or delayed information that
could cause non-serious injury of the patient, the operator, or both. A minor level of
concern is present when failure of the software product would not be expected to
result in injury to the patient or operator. The interrelationships of the three levels
34
of concern are analyzed in flow chart sequence.
Section Three of PreMarket Submissions sets forth the minimum types and
qualities of documentation needed to support FDA pre-market approval for medical
device software. To gain approval for medical device software involving a major level
of concern, the applicant must submit detailed documentation for each of the
following criteria:

29 Id.
30 Id. at

Appendix B. American National Standards Institute (ANS) and Institute of Electrical
and Electronic Engineers, Inc. (IEEE) standards are segregated into eight classes: General Life
Cycle Activities; Safety and Reliability; Quality Assurance; Configuration Management; Test and
Evaluation; Automated Tools; and Human Factors Engineering; see generally Anthony L. Young,
An Overview of ISO 9000 Applheation to Drug, Medical Device, and EnvironmentalManagement
Issues, 49 FOOD DRUG COSM. L.J. 469 (1994).
31 PremarketSubmissions, supra note 25, at Appendix C.
3 Id. at § 2.2.
3 Id. at § 2.2.1. A "serious injury" is defined as an injury or illness that is life threatening,
results in permanent impairment of a body function or permanent damage to a body structure, or
necessitates medical or surgical intervention to preclude permanent impairment of a body function
or permanent damage to a body structure. Id.; 21 C.F.R. § 803.3 (2003).
34 PremarketSubmissions, supra note 25, at § 2.2.1, Fig. 2.
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*

Level of Concern - the level of concern and supporting rationale;

*

Software Description - a comprehensive overview of the medical device
features that are controlled by the software;

" Device Features Controlled by Software - the role of the software in the
device, how the user interfaces with the software, which software
features can be modified by the user, and hardware over-rides or
backups;
" Operational Environment - the programming language, hardware
platform, operating system, and Off-the-Shelf components;
" Device Hazard Analysis - all device hazards associated with the
intended use, hardware and software;
" Software Requirements Specification - functional, performance,
interface, design and developmental requirements;
" Architecture Design Chart - the partitioning of the software into its
functional subsystems, a list of functional modules, and a description
of the role each module plays in the fulfilling the software
requirements;
" Design Specification - a high-level summary of the design and
specifications detailed enough such that a programmer is not required
to make ad hoc decisions;
" Traceability Analysis - a matrix linking requirements, design
specifications, hazards and validation;
" Development - the processes that are in place to manage the software
development life cycle, an annotated list of baseline documents, and
the configuration management and maintenance plan;
" Validation, Verification and Testing - a description of the verification
activities at the unit, integration and system level, and unit,
integration and system level test protocols including pass/fail criteria,
test report, summary and test results;
" Revision Level History - the revision log documenting all major
changes to the software during its development cycle;
" Unresolved Anomalies (Bugs) - each anomaly, the problem, the impact
on device performance, how they affect safety or effectiveness, and any
plans or timeframes for correcting the problem;
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*

Release Version Number - the release version number and date for the
5
software that will be included in the marketed device.3

To gain conditional pre-market approval to market major risk medical software,
the applicant must submit documentation to FDA describing ongoing risk
management, hazard analysis, risk estimation, risk control, and life-cycle risk
management activities. For each identified hazard, the applicant must identify the
risk control method used to eliminate the risk or reduce the risk to an acceptable
level, as well as the severity level after risk control methods have been implemented.
36
The goal is to reduce all software-related hazards to a minor level of concern.

2. Overview of "Off-the-ShelfSoftware Used In MedicalDevices"
FDA regulation of the use of Off-the-Shelf Software (OTS software) in medical
devices is based on the assumption that OTS software intended for general purpose
computing may not be appropriate for use in a medical device. OTS software
components are rapidly obsolete, they are easily changeable, and they are typically
37
not supported for long periods.
The type and amount of documentation to be provided to FDA on the use of OTS
medical software increases with the severity of the hazards to patients, operators, or
bystanders arising from the failure of OTS software.38 The regulation of OTS
software reflects a safety-based approach to risk management consistent with
39
international standards of risk management.
Applicants must provide a variety of basic documentation for each OTS software
component used in the applicant's medical device. The documentation must include:
* An
* The

exact identification of the OTS software;
computer system specifications for the OTS software;

'3 Id. at § 3.0. FDA premarket approval for sophisticated medical device software reaches all of
the components of software driven medical devices. Id. at § 1.3. See, e.g., CTR. FOR DEVICES AND
RADIOLOGICAL HEALTH, U.S. FOOD AND DRUG ADMIN., PREMARKET APPROVALS (Apr. 2002),
http://www.fda.gov/cdrh/pma/pmaapr02.html (FDA approval of protocol to for review of Image
Analysis system to be marketed by R2 Technology); CTR. FOR DEVICES AND RADIOLOGICAL HEALTH,
U.S.
FOOD
AND
DRUG
ADMIN.,
PREMARKET
APPROVALS
(Feb.
1997),
http://www.fda.gov/cdrh/pmafeb97.html (FDA approval granted for changes to the computer system
and operator's manual for deep heating ultrasound system to be marketed by Labthermics

Technologies, Inc.); CTR. FOR DEVICES AND RADIOLOGICAL HEALTH, U.S. FOOD AND DRUG ADMIN.,

PREMARKET APPROVALS (Jan. 2002), http://www.fda.gov/cdrh/pma/pmajan0O.html (FDA approval of
design changes consisting of the integration of data controller and associated software, the
replacement of a cubaclinical serial connector, and data controller operating instructions for a bone
sonometer to be marketed by McCue PLC).
36 PremarketSubmissions, supra note 25, at § 4.3.2.
'37Off-The -ShelfSoftware, supra note 26, at § 1.1.
38 Id.

39 Id. at § 1.2.
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*A
*

statement describing the function of the OTS software;

A statement describing the testing, verification and validation of the
OTS software for use with the applicant's medical device;

*A

statement describing how the applicant will insure the proper use of
40
the OTS software by End Users.

The applicant must also submit a software hazard analysis and a software
hazard mitigation analysis, and he or she must justify all residual risks associated
with the use of OTS software. 4 1 Should the OTS software itself represent a major
level of concern, the applicant must provide assurance to the FDA that the product
development methods used by the OTS software developer were sufficient to support
the secondary use of the OTS software in the applicant's device.
The FDA specifically warns that if the applicant is unable to properly audit the
OTS software developer's software design and development methodologies and
cannot properly mitigate all related hazards, the use of the OTS software is not
appropriate for the intended application. The applicant must take steps to assure
the FDA that the original developer will maintain the OTS software or establish
42
escrow arrangements to insure continued access to the OTS software code.

3. Overview of "GeneralPrineiplesof Software Validation"
Software Validation requires medical software developers to determine the
proper integration of software life cycle risk management activities, to document the
use of the proper programming approach, to describe the combination of software
engineering techniques to be used, and to indicate the level of support to be provided
43
to the medical software product.
Software Validation sets forth a new operational parameter for medical software
in that medical software must be "validated." Validation is "confirmation by
examination and provision of objective evidence that software specifications conform
to user needs and intended uses, and that the particular requirements implemented
through software can be consistently fulfilled." 44 Validation is the process by which
the medical device software provider demonstrates "a level of confidence before
shipping the product that the device meets all requirements and user expectations
45
for the software automated functions and features of the device."
The FDA's "software validation" standard is based on these criteria:

10 Id. at § 2.1.
41Id. at §§ 2.2-2.4.
42 Id. at § 2.5.
43 Final Guidance, supra note 27, at § 2.4.
44 Id. at § 3.1.2.
45 Id

[2:259 2003]

The Next Wave

* Due to its complexity, the development process for software should be
more tightly controlled than the development process for hardware;
* The quality of software product is dependent primarily on design and
development with a minimum of concern for manufacture;
* The ability of programs to execute alternative series of commands
based on differing inputs, "branching," makes programs complex and difficult
to understand;
*

Testing alone cannot verify that software is complete and correct;

* Although

software may improve with age as latent defects are

discovered and removed, new defects can be introduced into software as
updates are issued;
*

Software failures occur without advance warning;

*

Insignificant changes in software code can create unexpected and
significant problems elsewhere in the program;

*

Software maintenance personnel are not typically those involved in the
original software development effort;

*

Time is needed to fully define and develop reusable software code and
46
understand the behavior of off-the-shelf components.

Software Validation includes a lengthy section describing a variety of life cycle
activities that "support a conclusion that software is validated."47 The new
regulations reach the very heart of medical software code.
To support a conclusion that a piece of medical device software has been
validated, the FDA may require the applicant to provide detailed documentation
demonstrating compliance with a host of software engineering, coding, testing and
maintenance activities, including:
*

Quality planning, requirements specification, design, construction or
coding, testing by the software developer, user site testing, and
48
maintenance and software changes;

*

Software risk analysis, traceability analysis, software design
evaluation, design communication link analysis, module test plan

46

Id. at § 3.3.
§ 5.

47Id. at
48 jd
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generation, integration test plan generation, and test plan
49
generation;
* Statement coverage, branch coverage, condition coverage, multi-

condition coverage, loop coverage, path coverage, and data flow
coverage;50
*

Module or component level testing, integration level testing, and
51
system level testing;

*

Anomaly (bug) evaluation, problem identification and resolution

tracking, proposed change assessment, task iteration, and
documentation updating.

52

Software Validation closes with a massive bibliography that identifies eleven
FDA References, thirteen "Other Government References," nineteen "International
and National Consensus Standards," seven "Production Process Software
References," and forty-eight "General Software Quality References."3

B. Health and Human Services Regulation of MedicalSoftware
HHS is empowered to regulate the use of "health information" pursuant to the
Health Insurance Portability and Accountability Act. 5 4 HHS is about to publish final
regulations governing the electronic transmission of health information. 55 Health
information is defined as:
4 Id. at § 5.2.3.
50Id. at § 5.2.5. Techniques exist to determine what percentage of a software program has
been structurally evaluated. -d. If a testing program determines that a software program has
achieved "statement coverage," 100% of the statements in the software have been executed at least
once. Id.
,I-d.
I at § 5.2.6.
52 Id.at § 5.2.7.
53 Id. at Appendix A.
' Health Insurance Portability & Accountability Act, Pub. L. No. 104-191, 110 Stat. 1936
(1996).
55 For a look at the evolution of proposed rules applicable to electronic transactions, see The
Health Care Financing Administration, Security and Electronic Signature Stands: Proposed Rule,
U.S. Department of Health & Human Services (Aug. 12, 1998). 45 C.F.R. § 142 (1998). Portions of
the proposed rule applicable to eight types of electronic transactions now appear in Health

Insurance Reform: Standardsfor Electronic Transactions,45 C.F.R. §§ 160, 162 (1998). Publication
of the remaining portions of the proposed rule are pending. Id. The regulations are intended to
establish a flexible, scalable approach that requires organizations wishing to conduct electronic
exchanges of medical information to implement necessary measures to protect the confidentiality
and integrity of the data exchanged. Id. Portions of the proposed rule became effective in October,
2002 for health care clearinghouses and health care providers that choose to transmit any of the
transactions in electronic form. An effective date of October, 2003, was enacted for small health care
plans. Id.,* see U.S. Department of Health and Human Resources, Frequently Asked Questions
About
Electronic
Transaction Standards Adopted
Under
HIPAA,
available
at
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[A]ny information, whether oral or recorded in any form or medium
that -Is created by a health care provider, health plan, public health
authority, employer, life insurer, school or university, or health care
clearinghouse; and
Relates to the past, present, or future physical or mental health or
condition of the individual; the provision of health care to an
individual, or the past, present, or future payment for the provision
56
of health care to an individual.
The HHS regulation will govern the enormous volume of health information
generated by the American health care industry in various ways, including:
*

"Group health plans"57 having 50 or more "participants" or those
administered by an entity other than the employer that established
58
and maintains the plan;

*

"Health insurance issuers" 59 including insurance companies and
businesses providing services to insurance organizations licensed to
engage in the business of insurance in a State and are subject to State
60
law regulating insurance;

*

"Health maintenance organizations;"' 61

*

Part A or Part B of the Medicare program; 62

*

The Medicaid program; 63

aspe.hhs.gov/adminsimp/faqtx.htm (last visited April 15, 2003); U.S. Department of Health and
Human Resources What are the MajorDifferences Between the ProposedRule and the FinalRule,
available at aspe.hhs.gov/adminsimp/faqtxdif.htm (last visited April 15, 2003); see also Health
Insurance Reform, Security Standards, 45 Fed. Reg. 8334-01 (Feb. 20, 2003) (to be codified at 21
C.F.R. §§160, 162 and 164). This final rule adopts standards for the security of electronically
protected health information to be implemented by health plans, health care clearinghouses, and
certain health care providers. Id. The use of the security standards will improve the Medicare and
Medicaid programs and other federal and private health programs, as well as the effectiveness and
efficiency of the health care industry in general, by establishing a level of protection for certain
electronic health information. Id.
56 Health Insurance Portability & Accountability Act, Pub. L. No. 104-191, § 1171(4), 110 Stat.
1936, 2022 (1996).
57 See 42 U.S.C. § 300gg-91(a)(1) (2000).
58 See generally Employee Retirement Income Security Act, Pub. L. No. 93-406, 88 Stat. 829
(1974) (codified as amended at 29 U.S.C. §§ 1001-1461 (2000)).
59 See 42 U.S.C. § 300gg-91(b)(2) (2000) (defining "Health Insurance Issuers").
60 Id.

§ 300gg-91(b)(3) (2000) (defining "Health Maintenance Organization").
See 42 U.S.C. § 1395 (2000).
63 See 42 U.S.C. § 1396.
61See 42 U.S.C.
62
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*

Medicare supplemental policies; 64

*

The health care program for active military personnel; 65

* The

veterans health care program; 66

* The

Federal Employees Benefits Program.67

*

"Any other individual or group health plan or combination that
68
provides or pays for the cost of medical care."

The HHS regulation specifically applies to "individually identifiable health
information," defined as:
"[Information that --a. is created or received by a health care provider, health plan,
employer, or health clearinghouse; and
b.

relates to the past, present or future physical or mental health or
condition of an individual, the provision of health care to an
individual, or the past, present, or future payment for the
provision of health care to an individual, and
i. identifies the individual, or
ii. with respect to which there is a reasonable basis to believe
that the information can be used to identify the
69
individual."

The electronic exchange of "individually identifiable health information"
between two parties to "carry out financial and administrative activities related to
health care" will constitute a "regulated transaction."70 Regulated transactions shall

61 See

42 U.S.C. § 1882(g)(1) (2000). A "Medicare supplemental policy" is a health insurance

policy that a private entity offers to a Medicare beneficiary to provide payment for expenses incurred
for services and items that are not reimbursed by Medicare. Id.
65 See 10 U.S.C. § 1074 (2000).
66 See 38 U.S.C §§ 1101-2411(2000).
67See 5 U.S.C. § 8901 (2000).
68 See Security and Electronic Signature Standards, 63 Fed. Reg. 43241-80 (proposed Aug. 12,
1998) (to be codified at 45 C.F.R. pt. 142), avaikble at
http://www.hipaadvisory.com/regs/Regs in PDF/security-electronic-sign-stand.pdf.
6 See 42 U.S.C. § 1171(6) (2000).
70 See 42 U.S.C. § 1173(a)(2).
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include the electronic exchange of "First Report of Injury" data 71 and "Health Claims
2
Attachment" data.

III. THE INTELLECTUAL PROPERTY LANDSCAPE

A. Software Programsand Trade Secret/UnfairCompetition Law
Most states grant computer software trade secret protection pursuant to the
Uniform Trade Secrets Act or the Restatement (Third) of Unfair Competition. The
Uniform Trade Secrets Act defines a trade secret as information, including any
formula, pattern, compilation program, device or process, which derives independent
value from not being generally known and which is the subject of reasonable efforts
to maintain its secrecy. 73 The Restatement of Unfair Competition § 39 defines a
trade secret as any formula, pattern, device or compilation of information that is used
in one's business that provides opportunity or advantage over competitors who do not
74
know or use it.
Trade secret protection extends to ideas and processes contained in software
programs, as well as to the specific expressions of them. Protection does not depend
on novelty or uniqueness. So long as secrecy is maintained, protection continues in
perpetuity.
Software programming information may qualify for trade secret protection,
depending on: the degree to which the information is known outside the
programmer's business; the extent to which the information is known by employees
and others involved in the business; the measures taken to maintain secrecy of the
information; the value of the information; the amount of effort or money used to
develop the information; and the degree of difficulty required by others to properly
75
acquire the information.
Trade secret protection is premised on proof of "misappropriation." Protection
extends only insofar as a plaintiff can prove that the defendant's access to the
plaintiffs trade secrets was the result of an improper abuse of a confidential
relationship between them. 76 Once a product is made available to the general public,
competitors can lawfully attempt to discern trade secrets built into software by
71 See Security and Electronic Signature Standards, 63 Fed. Reg. at 43248.
"First Report of
Injury Transactions" may report information pertaining to an injury, illness, or incident to entities
interested in the information for statistical, legal, claims and risk management requirements. Id.
2 Id. at 43265.
Health claims attachments may report information used to transmit health
service information, such as subscriber, patient, demographic, diagnosis, or treatment data for the
purpose of a request for review, certification, notification, or reporting the outcome of a health
services review. Id.

73 UNIFORM TRADE SECRETS ACT § 1(4) (1985).
71 RESTATEMENT (THIRD) OF UNFAIR COMPETITION

the RESTATEMENT OF TORTS § 757 (1939).
75 See RESTATEMENT (THIRD) OF TORTS § 757 (1998).
76 UNIFORM TRADE SECRETS ACT at

§

1(2) (1985).

§

39 (1995). This definition is based upon
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reverse engineering, copying, or using the software.77 A party who misappropriates
78
trade secret information may not lawfully use the information for commercial gain.
As the term implies, trade secrets need not be recorded or registered with third
parties, as disclosure would strip away the secrecy component.
Pursuant to the Uniform Trade Secrets Act, a plaintiff must prove that he took
"reasonable measures" to protect the secrecy of the information. 79 What constitutes
reasonable measures is a factual question balancing an estimation of the costs and
benefits of varying levels of protection by persons knowledgeable in the particular
field.80 The more the owner of the trade secret spends to protect the information, the
more he demonstrates that the secret has real value deserving of legal protection,
that he was hurt by result of misappropriation of it, and that misappropriation
occurred.8 1 The use of non-disclosure agreements isconsidered to determine whether
plaintiff acted reasonably.
Third parties are not precluded from independently discovering and using trade
secrets held by others. Should a third party independently discover the trade secrets
of another, the third party may obtain a patent in the discovery and exclude the
82
original inventor from using, marketing, or licensing the former trade secret.
Once a trade secret enters the public domain, the law will not restrict the
subsequent use of the underlying information by third parties. The holder of a
former trade secret may seek damages from or injunctive relief against the person or
entity that misappropriated the former trade secret. The courts will probably not
issue injunctive relief restraining subsequent dissemination of former trade secret
83
information on First Amendment grounds.

B. Software Programsand CopyrightLaw
Copyright protection is granted to original works of authorship fixed in any
tangible medium of expression, now known or later developed, from which they can
be perceived, reproduced or otherwise communicated.8 4 Copyright does not protect
ideas, processes, or methods of operation.8 5 The Copyright Act has been amended to
include a definition of a computer program as "a set of statements or instruction to be
8' 6
used directly or indirectly in a computer in order to bring about a certain result.

77 Bonito

78 See

Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 155 (1989).

e.g. Speech Tech. Assoc. v. Adaptive Comm. Sys., Inc., 1994 U.S. Dist. LEXIS 11660, 26

(N.D. Cal. Aug. 16, 1994); DVD Copy Control Ass'n v. Bunner, 113 Cal.Rptr.2d 338 (6th App. Dist.
2001).
7) Rockwell Graphic Systems, Inc. v. DEV Industries, Inc., 925 F.2d 174, 179 (7th Cir. 1991).
80 Id
SI See
82 See

id.
generallyW.L. Gore & Assoc., Inc. v. Garlock, Inc., 721 F.2d 1540, 1545 (Fed. Cir. 1983)

(describing failed attempt by inventor of Gore-tex fabric manufacturing process to maintain trade
secret protection over manufacturing process).
8:3DVD Copy Control Ass'n, 113 Cal.Rptr.2d at 340.
M 17 U.S.C. § 102(a) (2000).
85 17 U.S.C. § 102(b) (2000).
86 17 U.S.C. § 101 (2000).
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Copyright protection extends only to the author's form of expression, not to the
idea that was the basis of the author's expression. 87 That rationale flows from the
decision of the Supreme Court in Baker v. Selcen. The Court reasoned, "Copyright of
a work on mathematical science cannot give to the author an exclusive right to
methods of operation he propounds, or the diagrams which he employs to explain
them."88 Lower federal courts have limited the rule, reasoning that if there are only a
finite number of ways to express an idea, the idea does not qualify for copyright
protection.8 9 Thus, where an idea and the expression of the idea become inseparable,
the expression of the idea does not qualify for copyright protection. 90
The courts have struggled to determine the boundaries of copyright protection of
computer software programs. Non-literal elements of software have been given
limited protection. A minority of courts follows the rule expressed in Whelan Assoc.
v. Jaslow Dental Labs., Inc., that extends copyright protection to the structure,
sequence, and organization of a computer program. 91
The majority of courts follow the complex "abstraction-filtration comparison test"
devised by Judge Learned Hand in Nichols v. Universal Pictures Corp.92 Judge
Hand's test requires the court to segment programs on the basis of varying levels of
abstraction. First, the general idea is identified; implementation of the idea in
program sub-segments follows. Each of the sub-segments are tested to determine
whether they may qualify for copyright protection. Segments of the program that
can be expressed in no other way, segments dependent upon external factors, and
segments in the public domain, do not qualify for copyright protection.
The
remainder of the program - the essence of programmer's creative expression - can
93
obtain copyright protection.
Under either test, substantial portions of software programs that contain
material in the public domain or non-creative expression do not qualify for copyright
protection. Specialized medical software programs containing new algorithms are
much more likely to qualify for copyright protection than are programs in widespread
general use.
The holder of the copyright is granted the exclusive right to make copies of the
program, to prepare derivative works of the program, and to distribute copies of the
program. 94 The copyright holder may not bar others from using similar programming

87 17

U.S.C. § 102(b) (2000).

101 U.S. 99 (1879).
89Seo, e.g., Gates Rubber Co. v. Bando Chem. Indus., Ltd., 9 F.3d 823, 836 (10th Cir. 1993)
88

(detailing the "idea-expression dichotomy" with respect to computer programs).
90Id. at 838. This idea is central to the merger doctrine, which allows for denial of copyright
protection to an expression that relies upon underlying ideas, processes, or discoveries. d.
91797 F.2d 1222 (3d Cir. 1986).
92 45 F.2d 119, 121 (2d Cir. 1930) (explaining the need for consideration of abstractions with
respect to a play, because "as more and more of the incidents are left out ....
there is a point in this
series of abstractions where they are no longer protected, since otherwise the playwright could
prevent the use of his 'ideas,' to which, apart from their expression, his property is never
extended.").
93 See Computer Assoc. Int'l, Inc. v. Altai, Inc., 982 F.2d 693, 710 (2d Cir. 1992) (terming the
leftover elements the "golden nugget" of the work's copyright value).
94 17 U.S.C. § 106 (2000).
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techniques to achieve the same general result. 95 Unless prohibited by contractual
terms, reverse engineering of a computer program is lawful so long as the effort is
96
made to discover non-protected or non-protectable portions of the program.
Once the program is fixed in a tangible medium copyright protection attaches
automatically. 97 The term of protection is for the life of the author plus seventy
years, or if the work was made for hire, for the first to expire of either seventy-five
years from first publication or 100 years from creation. 98 Publication is not
required. 99 Registration is required to bring an action for enforcement. 10 0

C.Software Programsand PatentLaw

1. Overview
The United States Constitution explicitly provides for the creation of patent
10 2
for a limited term.10 3
rights 0 1 that confer a monopoly on the holder of the grant
The invention must be a machine, article or manufacture, process, or composition of
matter. 104

If the patent owner can demonstrate to the satisfaction of the United States
Patent and Trademark Office (PTO) that the invention is useful, novel, not a law of
10 5
nature or science, and non-obvious to one reasonably skilled in the applicable art,
the PTO may issue a patent. Of particular importance, the applicant for a computer
software patent must disclose the "best mode" of program operation; failure to
disclose the "best mode" can constitute grounds for denial of a patent by the PTO or
10 6
the issuance of a court order declaring a patent issued by the PTO invalid.

9517 U.S.C. § 102(b) (2000).
96 See Sega Enters., Ltd. v. Accolade, Inc., 977 F.2d 1510, 1527 (9th Cir. 1992).
9717 U.S.C. § 102(a) (2000).
9817 U.S.C. § 302 (2000).
99Id.
100 17 U.S.C. § 412 (2000).
101See U.S. CONST. art. I, § 8, cl. 8 ([T]he Congress shall have the Power to promote the
Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the
exclusive Right to their respective Writings and Discoveries.").
102 See 35 U.S.C. § 271 (2003). The patent owner may prohibit others from making, selling, or
offering for sale the patented invention in the United States. Id.
103 See 35 U.S.C. § 154(c)(1) (2003). For patents issued on or after June 8, 1995, the term of the
patent is twenty years from the date of application. Id. For patents issued before June 8, 1995, the
term is the longer of seventeen years from issue, or twenty years from date of filing. Id.
104 35 U.S.C. § 101 (2003).
105 35 U.S.C. §§ 101-03 (2003).
106See, e.g., White Consol. Indus. v. Vega Servo Control, Inc., 713 F.2d 788 (Fed Cir. 1983).
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2. Software Patents
For many years, the PTO refused to grant patents in software, holding that
software was a set of mathematical equations and algorithms that, standing alone,
were not new processes. The policy was changed in Diamond v. Diehr.10 7 There, the
United States Supreme Court held that a mathematical algorithm included in a
software application could qualify for patent protection so long as the software
application was part of a larger patentable process. Subsequent case law has firmly
established patent protection for software.108 Software patents have been granted for
inventions governing system functions, as well as those involving the use of a mouse,
speech recognition, and display functions. 10 9
The PTO has issued guidelines governing the patentability of computerimplemented inventions.110 The PTO guidelines state that a computer program is a
"machine." Additionally, computer memory is defined as an article of manufacture,
111
and a series of steps controlled by a computer is designated as a "process."
Initially, the software industry did not seek software patents. The industry
included many new ventures that did not wish to incur the expense of patent
protection and that voiced opposition to software patents in general.
Oracle
Corporation publicized an official company policy opposing the patentability of
software-related inventions.11 2 In 1991, Microsoft owned ten United States patents.
Reflecting the growth of the Internet and the liberalization of laws and policies
governing the grant of software patents, the attitude of the industry has changed. By
February 2002, Microsoft owned more than 2,000 U.S. patents. Oracle, patentdeprived through 1994, was known to hold to 249 patents in 2001.113

3. "BusinessMethod" Software Patents
For many years, the courts routinely held that a patent should not be granted
for "a system of transacting business disconnected from the means of carrying out the
system."11 4 Even the Patent and Trademark Office was unclear as to the status of
business methods, stating that while they could fall within the method or process
11 5
categories, they can none-the-less be rejected for lack of patentable subject matter.

107

450 U.S. 175 (1981).

108 See, e.g., In re Alappat, 33 F.3d 1526 (Fed. Cir. 1994) (holding that software program that

created a smooth waveform suitable for display on a digital oscilloscope could be patented).
109 See U.S. Pat. No. 5,443,068 (issued Aug. 22, 1995); U.S. Pat. No. 5,440,663 (issued Aug 22,
1995); U.S. Pat. No. 5,442,742 (issued Aug. 15, 1995); U.S. Pat. No. 5,394,546 (issued Feb. 25, 1995).
110 Examination Guidelines for Computer-Implemented Inventions, 61 Fed. Reg. 7478 (Mar.
28, 1996).
111 Examination Guidelines, 61 Fed. Reg. 7478 at IV.B.2(a)(ii).
112Id.; see Oracle Company-PatontPolicy,at
http ://www.base.com/softwarepatents/statements/oracle.statement.html.
113 T. Andrew Culbert, Loecturo on Legal Issues ConeorningSoftware Patents (Apr. 23, 2002).
11 Hotel Security Checking Co. v. Lorraine Co., 167 F. 460, 469 (2d Cir. 1908).
115 See State Street Bank & Trust Co. v. Signature Financial Group, Inc., 149 F.3d 1368 (Fed.
Cir. 1998).
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The Federal Circuit abolished the rule prohibiting the patentability of business
116
methods in State Street Bank & Trust Co. v. Signature Financial Group, Inc.
Reasoning that "patentability does not turn on whether the claimed method does
'business' instead of something else, but on whether the method viewed as a whole,
meets the requirements of patentability," the court reversed a PTO holding denying a
grant of patent for a software system used to manage a "hub and spokes" financial
117
accounting structure.
The combined effects of the changes in judicial and regulatory policy and the
widespread adoption of the World Wide Web led to a rush on the PTO. Many
businesses sought business method patents to capitalize on technologies developed
118
for the commercialization of the Internet.
It became apparent that the PTO had insufficient resources and technical
expertise to deal with demand. 119 In response to concern about the quality and legal
validity of business method patents, the PTO issued a Business Methods Patent
Initiative. 120 The PTO dedicated itself to work more closely with software, Internet
and electronic commerce ventures in order to enhance the technical training and
expertise of patent examiners and to revise guidelines governing standards for
121
patentability for computer-related inventions.
At the same time, the courts began focusing on the legal sufficiency of business
methods patents. 122 Relying on its newly issued "One-Click" e-commerce business
method patent, Amazon.com attempted to enjoin similar e-commerce operations by
BarnesAndNoble.com. Although the battle initially went Amazon's way, the Federal
Circuit held that Barnes & Noble raised sufficient challenges to the validity of the
Amazon "business method" patent that a trial on the merits was required. 123
Measured against the backdrop of other significant patent policy matters, 124 the
trend appears to be that business method software patents will be given close judicial
scrutiny, and that business method patentees can expect serious challenge from
125
alleged infringers.

116Id.
117

Id. at 1375.

118 Culbert, supra note 113.
19 Id.
120 Business Methods PatentInitiative:An Action Plan, United States Patent and Trademark
Office, available at http://www.uspto.gov/web/offices/com/sol/actionplan.html.
121Id.
122 Culbert, supra note 113.
12: Amazon.com, Inc. v. BarnesAndNoble.com, Inc., 239 F.3d 1343 (Fed. Cir. 2001).
124 The Supreme Court, in Festo Corp. v. Shoketsu Knzoku Kogyo Kabus-hiki Co., 535 U.S. 722

(2002) (holding that there was a flexible estoppel bar rather than an absolute estoppel bar), recently
vacated the Federal Circuit's 1998 decision.
125 Culbert, supra note 113; A patent entitled "Medical Network System and Method for
Transfer of Information," issued to MEDWEB, INC., is one of the first of several patents granted or
pending for the routing, management and display of medical imagery data and display over the
Internet. U.S. Pat. No. 6,424,996 (issued July 23, 2002). Patents of that type may be subject to
more exacting scrutiny by a reviewing court. Id.
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IV. THE CONTRACT LAW LANDSCAPE

A. Software Programsand ContractLaw
Article 2 of the Uniform Commercial Code (UCC), the primary body of
commercial contract law in the United States, has long characterized commercial
contracts on the basis of the delivery of "goods" or "services." Transactions involving
the sale of goods and services are to be characterized using the "dominant purpose"
test. If the dominant purpose of the transaction is determined to be the supply of a
good, Article 2 governs the transaction. If the dominant purpose of the transaction is
determined to be the supply of a service, the transaction is governed by rules of
general contract law. The UCC does not provide clear guidance when the contracted
for activity calls for the generation, capture, comparison analysis and transmission of
126
information by medical devices.
American courts have begun taking the position that computer software
transactions should be construed in keeping with the principles governing the sale of
goods outlined in Article 2.127 Article 2 provides for the imposition of an implied
contractual term or warranty with respect to the merchantability of goods. American
128
courts have implied the warranty of merchantability to software transactions.
Goods sold for a particular purpose are also subject to the imposition of more
stringent contractual terms than those for mass-marketed goods.1 29 Article 2
1 30
provides an implied warranty of fitness for a particular purpose.

B. Medical Software Contract-BasedPerformanceDuty
American courts have been reluctant to imply terms to contracts that call for the
provision of "services." The supplier of a service has traditionally been placed under
a contractual duty to carry out the contracted-for services with reasonable care and
skill. The Restatement (Seeond) of Torts defines a supplier as "one who undertakes
to render services in the practice of a profession or trade [and] is required to exercise

126 See generally Noriko Kawawa,
Contractual Liability for Defects in Information in
Electronic Form, 8 BALT. INTELL. PROP. L.J. 69 (1999-2000) (analyzing the law of contracts, torts,

and the Uniform Computer Information Transactions Act).
Neilson Bus. Equip. Ctr. Inc. v. Monteleone, 524 A.2d 1172 (Del. 1987).
U.C.C. § 2-314 (1998). The tests for determining merchantability include whether the goods
are fit for the ordinary purposes for which such goods are used; whether the goods are adequately
labeled as the agreement may require; and whether the goods conform to the promises or
affirmations of fact made on the container or label. Id.; see also NoilYson, 524 A.2d at 1172-76
(applying implied warranty of merchantability to computer system).
129U.C.C. § 2-314 (1998).
1:30U.C.C. § 2-315 (1998).
The implied warranty of fitness for a particular purpose can be
attached if the seller at the time of contracting has reason to know any particular purpose for which
the goods are required, and the buyer is relying on the seller's skill or judgment to select or furnish
suitable goods. Id.
127

128
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the skill and knowledge normally possessed by members of that profession or
13 1
trade."
Where a professional or trade standard can be proven to exist, the courts may
impose a duty of performance at a level commensurate with that standard. 132 The
performance of services provided by American medical and legal professionals are
subject to the higher standard.133
The new FDA and the proposed HHS regulatory frameworks that govern the
life-cycle architecture, programming, distribution, and maintenance of medical device
software establish a minimum level of skill and competence that must be observed by
those who supply medical device software for use in the American health care
market. While it is within the capacity of parties to a medical device software
contract to attempt to disclaim implied warranties of merchantability or fitness for a
particular purpose, 134 contractual terms attempting to disclaim the performance of
medical software technology contracts in accordance with either the existing FDA or
the proposed HHS regulatory software standards are contrary to public policy and
unenforceable. 135

C. Software Programsand the ProposedAdoption of The Uniform Computer
Information TransactionsAct
A movement is underway to create the Uniform Computer Information
Transactions Act (UCITA), a new body of law that will supply rules governing the
licensing of computer software and "computer information transactions."1 3 6 In
keeping with its scope, complexity and importance, UCITA has been the subject of
great controversy.1 37 So far, only two states, Maryland and Virginia, have enacted

§ 552(1) (1976).
1:329 S. WILLISTON, A TREATISE ON THE LAW OF CONTRACTS, § 1012 C (3d ed. 1967
1:31RESTATEMENT (SECOND) OF TORTS

& Supp.

1987).
1:3:3
ITd
1:1 To attempt to disclaim an implied warranty, the disclaimer must conform to the
requirements of U.C.C. § 2-316 as interpreted by the courts. In addition to being "conspicuous" and
"inwriting," attempted disclaimers must survive judicial interpretation of the effects of integration
clauses or the doctrine of unconscionability.
135 U.C.I.T.A., § 406(c) (1999).
UCITA allows disclaimer of implied warranties unless the
disclaimer would be manifestly unreasonable, pre-empted by federal law, or in violation of a
fundamental public policy. Id.
136 See Draftfor App-roval of Uniform Computer and Information TransactionsAct, available at
http://www.law.upenn.edu/bll/ulc/ucita/citam99.htm (last visited April 15, 2003); see also UCITA
Developments,
National
Conference
of
Commissioners
on
Uniform
State
Laws,
http://www.nccusl.org/nccusl/ucita/UCITA StandbyComm.htm (last visited April 15, 2003).
137 See generally UCITA Developments, National Conference of Commissioners on Uniform
State Laws, at http://www.nccusl.org; Letters, Statements, Testimony, Resources, Article 2B of the
Uniform Commercial Code, Uniform Computer Information Transactions Act, Association of
Research Libraries, Washington, DC at http://www.arl.org/info/letters/index.html; American Bar
Association Working Group Report, Uniform Computer Information TransactionsAct ("UCITA '9, at
http://www.necusl.org/nccusl/ucita/UCITAStandby-Comm.htm (last visited April 15, 2003).

[2:259 2003]

The Next Wave

versions of UCITA into law. A nationwide lobbying effort is underway to convince
138
additional state legislatures to enact UCITA.
A recent American Bar Association Working Group Report harshly criticizes
UCITA and recommends that it be completely redrafted. 13 9 Proponents of UCITA
oppose redrafting and have offered a number of amendments to UCITA to satisfy
140
objections raised by the Working Group Report.

1. Software Integrated with or Embedded into Goods
Of particular interest here, the ABA Working Group Report criticized the
approach UCITA used to resolve issues involving "computer software that is
integrated into goods," asserting instead that:
It is important for users of UCITA to know whether UCITA applies
or does not apply to a particular transaction. One of the most
difficult and challenging questions raised by UCITA is the extent to
which UCITA should apply to software that is integrated into goods.

UCITA addresses this issue by asking two questions: (1) [Wihether
the goods are a "computer" (which is defined as an electronic device
that accepts information in digital or similar form and manipulates
138

See Next Few Months the NCCUSL Will Prepare to Take Article 2, UCITA Changes on the

Road, Computer Technology Law Report, Vol. 3, No. 17 (Sept. 6, 2002); NCCUSL Adopts All

Proposed Amendments to UCITA with Some Adjustments to Text, Computer Technology Law
Report, Vol. 3, No.16 (Aug. 6, 2002); UCITA Drafters Will Entertain Proposals to Make Licensing
Law Consumer-Friendly,Computer Technology Law Report, Vol. 2, No. 22 (Nov. 16, 2001).
139 As its primary criticism, the ABA Working Group stated:
[UCITA] as presently drafted, is extremely difficult to understand. [UCITA] is a
very complex statute that is daunting for even knowledgeable lawyers to
understand and apply ....
[M]any of the "black letter" rules come across as
convoluted and at times, inscrutable. Time and again, when the Working Group
attempted to consider the substantive merits of a UCITA concept or provision, the
Group had to parse through the language word by word and clause by clause, only
to realize, in the end, that the individual members of the Group could not agree on
what the particular section said or meant.
Accordingly, the Working Group is concerned that UCITA, as presently drafted,
would not achieve the principal objective that a uniform law is expected to
achieve, namely, the establishment of a high level of clarity and certainty in a
particular area of the law.
To the contrary, the Working Group is concerned that if UCITA, in its present
form, goes forward, there would be considerable controversy and litigation over
what its various "rules" really mean.... [T]he Working Group believes that
UCITA should be redrafted to make it easier to understand and use.

American
Bar
Association
Working
Group
Report,
supra
http ://www.nccusl.org/nccusl/ucita/UCITAStandby-Comm.htm.
110 Id. at 9; see also U C.I TA. 2002 Revisions:Memo and Chart,availableat
http://www.nccusl.org/nccusl/ucita/UCITA_082602_MEMO-andCHART.pdf
2002).

note

137,

(last visited Aug. 23,
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it for a result based on a sequence of instructions") or a "computer
peripheral" (which term is not defined), and (2) whether access to or
use of the software contained in and sold or leased as part of the
goods is "ordinarily a material purpose of transactions in goods of
the type sold of leased ......
If either the "computer or computer peripheral" test or the "material
purpose" test is met, then UCITA applies to the software, and other
law, presumably UCC Article 2 (sales of goods) or 2A (leases of
goods), applies to the goods. If, on the other hand, either test is not
met, the transaction is not governed at all by UCITA, but is instead
governed by other law, presumably once again, Article 2 or 2A....

Members of the Working Group felt that this approach created
uncertainties and was difficult to apply. The word "computer" is so
broadly defined that any goods containing a computer chip might be
construed to be a "computer," raising the possibility that all
transactions for consumer electronic devices and most transactions
for commercial equipment would fall within the scope of UCITA. ...
Although the Comments to UCITA attempt to explain how the
"material purpose" test should be applied to particular transactions,
the Working Group is not confident that the Comments are
consistent with the text in their conclusions ......
The Working Group recognizes that there may be no bright line to
decide when goods with integrated software should be governed,
even in part, by UCITA and that any formulation of a resolution will
not be perfect. ...
However, it is the view of the Working Group that the line drawn by
UCITA could be better formulated to meet the normal and
reasonable expectations of the parties. ...
[A] better formulation would minimize, for transactions involving
the sale or lease of goods with integrated software, the possibility of
two different bodies of law -- UCITA and typically Article 2 or 2A --

applying to a sale or lease transaction of a single product.
Application of dual legal rules for a single transaction would be
especially problematic, given, among other things, the different
contract formation provisions and third party rights afforded by each
set of rules....
The Working Group believes that a better approach, more consistent
with buyer or lessee expectations, would be a formulations based on
how the goods are marketed. When software is embedded in and
marketed as an integral part of goods, many, if not most, people
would consider software to be part of the goods. UCITA therefore
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should not apply to the sale or lease of the goods (containing
integrated software). Rather, the sale or lease of (goods containing
integrated software) should be governed by Article 2 or 2A....
It would necessarily follow under this formulation that software
could still be marketed with goods, so that UCITA would apply to
the software but other law would apply to the goods. For example,
software loaded onto a general-purpose computer and licensed with
the computer would be such a mixed transaction, with UCITA
applying to the license for the software and other law applying to the
sale of the computer....
Similarly, the license of software loaded onto an appliance but
intended to be used with the appliance, the software license would
be governed by UCITA while the transaction involving the
acquisition of the appliance would be governed by other law. In most
cases involving the sale or lease of the goods themselves, in contrast
to the license of the software, the other law would be UCC article 2
or 2A, which would apply to the transactions in the goods
141
themselves.
In response, the proponents of UCITA, the National Conference of
Commissioners on Uniform State Laws (NCCUSL), reiterated the rationale they used
to draft the provision:
Action: The drafting committee had tried many suggestions,
including (the approach suggested by the Working Group), before it
settled on the approach in UCTA....
[Tihe Committee believes that the current approach best offers
guidance to courts and parties for deciding what law should apply.
The definition of goods in amended Article 2 of the UCC, recently
approved by NCCUSL, excludes "information." The Preliminary
Comments to amended Article 2 and the Official Comments to
UCITA state that chips (software) embedded in goods in most cases
will be governed by UCC Article 2. However, as the working group
acknowledges, there is no bright line and in some cases the court will
have to determine whether a particular transaction is an
information transaction subject to the common law or UCITA, or a
goods transaction subject to UCC Article 2.142

"I American BarAssociation Working Group Report, supra note 137, at
http ://www.nccusl.org/nccusl/ucita/UCITAStandby-Comm.htm.
142 UC.I.TA. Developments, National Conference of Commissioners on Uniform State Laws,
U.C.I.T.A. 2002 Revisions: Memo and Chart, Section I. Scope (Aug. 23, 2002).
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For now, lawyers are left with a host of unresolved questions regarding the law
governing transactions involving "computer software integrated into or imbedded in
goods." Will the amended version of UCITA meet with a favorable response from the
legislatures of the various states? If the states choose to enact new law will the
states accept the position suggested by the proponents of UCITA, the position
suggested by the ABA Working Group, or will they devise others? How will the state
courts interpret and apply new laws involving "computer software integrated or
imbedded into goods?" How should medical software businesses structure their
relationships? Further development of the law is sure to follow.

2. Preview of Suggested New UCITA WarrantyLaw
As some portion of the UCITA warranty framework may become accepted
national law, a sampling of the UCITA warranty provisions is appropriate here.
Mindful of the criticism of the ABA Working Group about the complexity of UCITA
as currently drafted, the reader is urged to examine the cited UCITA provisions and
Reporter's Notes to form a professional opinion whether the UCITA warranty
provisions should serve as the basis for new national law.
UCITA, Part 4, suggests a new body of warranties be made applicable to
transactions governed by UCITA, including: Warranty and Obligations of Quiet
Enjoyment, Express Warranty, Implied Warranty of Merchantability of Computer
Program, Implied Warranty of Informational Content, and Implied Warranty of
143
System Integration.
The Warranty and Obligations of Quiet Enjoyment provisions hold that licensors
in transactions subject to the law will warrant that "no person holds a claim to or
interest in the information which arose from an act or omission of the licensor, other
than a claim by way of infringement or misappropriation, which will interfere with
the licensee's enjoyment of its interest." 144 Licensors of patent rights will warrant
that licensed patent rights are valid and exclusive to the extent that exclusivity and
validity are recognized. Merchant licensors will warrant that the "information" is
delivered free of the rightful claim of any third party way of infringement. Merchant
licensors may "quitclaim" informational rights without warranty as to infringement
145
or misappropriation.
The Express Warranty provisions provide for the creation of a warranty of an
"affirmation of fact or promise made by the licensor to the licensee .

.

. which relates

to the information and becomes part of the basis of the bargain." 146 An express
warranty will not be created for "an affirmation or prediction merely of the value of
the information or informational rights," a "display or description of a portion of the
information to illustrate aesthetics, market appeal, or the like, of informational

H3 U.C.I.T.A. § 401 (1999).

I- U.C.I.T.A. § 401(b) (1999).
"1 See generally U.C.I.T.A. § 401, Warrantyand Obligations Concerning Quiet Enjoyment and
Non -Infringement& Rptrs Notes (2003).
146

U.C.I.T.A. § 402 (1999).
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content," or "a state purporting to be merely the licensor's opinion or commendation
147
of the information or informational rights."
The Implied Warranty of Merchantability of Computer Program provisions
provide for the creation of an implied warranty of a merchant licensor that, unless
otherwise disclaimed or modified, the computer program will be reasonably fit for the
ordinary purposes for which it is distributed, that the program will be adequately
packaged and labeled, that the program will conform to the promises or affirmations
of fact made on the container or label, and that the warranty may arise form course
148
of dealing or usage of trade.
The Implied Warranty of Informational Content provisions provide that unless
otherwise disclaimed or modified, a merchant in a special relationship of reliance
with a licensee, who collects, compiles, processes, provides, or transmits
informational content, will warrant to the licensee that there is no inaccuracy in the
informational content caused by the merchant's failure to perform with reasonable
care. 149 The special element of reliance will arise from the relationship, a
relationship characterized by the provider's knowledge that the particular licensee
plans to rely on data in its own business and expects the provider to tailor the
150
information to its needs.
The Implied Warranty of System Integration provisions provide that, unless
otherwise disclaimed or modified, should a licensor have reason to know any
particular purpose for which the information is required, and should he have reason
to know that the licensee is relying on the licensor's skill or judgment to select,
develop, or furnish suitable information, the information will not fail to achieve the
151
licensee's particular purpose as a result of the licensor's lack of reasonable effort.
Additionally, the provisions create a new warranty meant to assure a licensee that
152
selected components will function as a system.
No matter what form the proposed new UCITA warranty provisions eventually
assume, counsel should always premise opinions regarding the enforceability of
medical device software warranty provisions in terms of the duty of the court to
render Justice. In that regard, Professor Peter Alces has persuasively argued that
software technology has yet to reach the level of context-based, relational maturation
such that the courts will likely resolve software disputes use "standard" warranty
provisions supplied by scholars. 153 To the contrary, Professor Alces cogently reminds

H7

Id. § 402.
§ 403.
U.C.I.T.A. § 404 (1999).

1"8 Id.
149

150 Id.
151U.C.I.T.A.

§ 405 (1999).

Id.
15:3 See Peter Alces, W(h)ither Warranty: The B()oom of Products Liabihlty Theory in Cases of
Deficient Software Design, 87 CAL. L. REV. 269 (1999). Courts seeking to do justice will likely resort
to the use of strict products liability law in the event that risk shifting warranty provisions fail to
strike the appropriate, context based, experientially oriented balance between the rights of
producers of software products and the rights of consumers of software product technology who are
harmed by the use of defective software. Id.
152
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us that the failure of warranty law to render Justice in medical software disputes
154
may open the door to the resolution of those disputes using the law of torts.

V. THE TORT LAW LANDSCAPE
The following excerpts, which appear in the FDA's online "Manufacturer and
User Facility Device Experience Database" (MAUDE), illustrate how the use of
155
medical device software can cause patient injury or death.
Software Programming:
Adverse Event or Product Problem Description:
Type of Device: Computed Tomography
Manufacturer: Siemens Medical Systems, Inc.
Date FDA Received: 12/22/2000
When the eval/magnify function is used in connection with over eval
functions, the result may be an incorrect display of the magnified
156
image.
Adverse Event of Product Problem Description:
Type of Device: Gama Camera
Manufacturer: Siemens Medical Systems Inc.
Date FDA Received: 4/20/2001
A device malfunction was identified. Under specific conditions software
will result in incorrect orientation of acquired patient data in "Spect"
mode. This occurs when switching from "Coincidence" mode to "Spect"
mode on the Ecam via the patient-positioning monitor, while at the same
time there is an acquisition workflow running. The incorrect orientation
may cause the displayed image to be reversed in either "left to right" or
"top to bottom" directions. It may not be immediately clear to the
operator that the image has been reversed. A potential for misdiagnosis
exists at that point.157
Software Labeling:
Adverse Event or Product Problem Description:
Type of Device: Radiation Therapy Planning Equipment
Manufacturer: ADAC Laboratories
Date FDA Received: 8/18/1999
151Id.
155MAUDE Data Base Record, Food & Drug Administration - Center for Devices and
Radiological Health (Emphasis supplied), available at
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfiMAUDE/Search.cfm (last visited Apr. 15, 2003).
156

Id.

157 I]d.
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The customer reports that while planning on a Siemens Primus machine
the treatment plan printout displays incorrect jaw labels. The Siemens
terminology used in jaw orientation specification differs from the
Pinnacle software jaw orientation terminology. The treatment plan
printout displays the Y jaws labeled as "width" and the X jaws labeled as
"length," although Y is in the patient SUP-INF direction and X is the
patient Left-Right direction. Confusion over the incorrect jaw labels
could lead to problems with the patient being set up incorrectly and/or
158
being treated with the incorrect shape field.
Adverse Event or Product Problem Description:
Type of Device: Medical Fluoroscopic Mobile C-Arm Software
Manufacturer: General Electric OEC Medical Systems
Date FDA Received: 9/8/2000
The calibration of the automatic brightness control, which regulates the
radiation output of the machine was set to excessive values for the "high
level pulsed fluoroscopy" mode of operations. OEC claims that their
service software does not provide for either means to adjust the
radiation dose rate, nor the option to turn off the "high level pulsed
fluoro" mode of operation. The purpose of this mode of operation is to
acquire a series of individual data images for a predefined time period "run time" - the individual image files are stored on the imaging
computer hard-drive for later retrieval. The images acquired during the
serial "run" can undergo automatic or operator controlled digital
processing such as image subtraction, edge enhancement, contrast scale
modification and serial playback ....
Instead of labeling the mode of
operation "digital acquisition" or "digital cine" (OEC) call it "high level
pulsed flouro." This is clearly a misnomer as the mode is not intended
159
for live fluoroscopic viewing.
Software Misuse:
Adverse Event of Product Problem Description:
Type of Device: Computer
Manufacturer: Radionics, a division of Tyco HealthCare
Date FDA Received: 1/04/99
This report is based on info supplied by others. Around the date of April
10, 1998, a surgeon used the wrong software package with companies
SCS1. The result was that the wrong coordinates were calculated, and
consequently, the hole was drilled in the wrong area of the patient's
head. Company sales representative from this area was asked to gather
info about this event on three separate occasions. These attempts were
made on April 21, 1998, May 1, 1998, and May 7, 1998 with no response.

158
159

Id.
Id.
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Company is currently in the process of evaluating the labeling of this
160
product to possibly additional warnings to the software packages.
Adverse Event or Product Problem Description:
Type of Device: Computerized Treatment Planning System
Manufacturer: Multidate Systems International Corp.
Date FDA Received: 6/16/2001
In public documents released by the International Atomic Energy
Agency (IAEA) and the US Nuclear Regulatory Commission (US NRC),
Multidate has become aware of a radiological emergency in Panama ....
The emergency involved a radiotherapy unit using a Cobalt-60
teletherapy machine and a computerized treatment planning system for
calculating radiation doses to be delivered to the patient.
[A
Panamanian] Health Minster said health officials changed their
procedures in administering the radiation treatment in order to get
better results and ended up giving the patients between 20% to 100%
more radiation than they should have. As reported, the incident
involved 28 patients who were treated at the [National Oncology
Institute of Panama] from 2000 through 2001 for colon, prostrate and
cervical cancer. Eight of the patients are reported to have died, and five
of the deaths have been attributed to the excess radiation received
during the treatments .... The practice at the facility was changed to

enter data in such a way as to appear to the treatment system to exceed
its limitation on shielding blocks, even though the user manual for the
treatment planning system not only clearly specifies the limit, but also
recommends that the results be verified by measurement before using. 161

A. Negligence Law
Attorney-software engineer Cem Kaner provides useful baseline observations
about the applicability of negligence law to computer software. Kaner explains,
"[Tihe essence of quality-related litigation is a customer seeking to transfer losses
caused by a defective product back to the company that made the defect or sold it.'162
Kaner surmises that the quality costs associated with software products include:
[e]xternal failure, technical support calls, preparation of support
books, investigation of customer complaints, refunds and recalls,
coding/testing of interim bug fix releases, shipping of updated
product, added expense of supporting multiple versions of the
product in the field, PR work to soften drafts of harsh reviews, lost
sales, lost customer goodwill, discounts to resellers to encourage
160 ITd
161Id.
162 Cem Kaner, The Law of Software Quality available at
http://www.kaner.com/pdfs/slides/amslaw.pdf (last visited Apr.15, 2003).
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them to keep selling the product, warranty costs, liability costs,
government investigations, penalties, and all other costs imposed by
law. 163
A customer who buys a defective product absorbs costs such as "wasted time,
lost data, failure during tasks that can only be done once, cost of replacing product,
reconfiguring the system, cost of recovery software, cost of tech support, and
injury/death. 164 Kaner adds that "[r]easonable consumers have reason to sue if [the
manufacturer's/seller's] products' failures cost them more than their cost and
165
aggravation from litigation."

1. Software Programs, the Law of Generaland ProfessionalNegligence, and the
Supply of Me dicalDevice Software
A showing of the elements of a negligence action are proof that defendant was
subject to a legal duty to exercise reasonable care, that defendant breached the duty
of care, that defendant's breach of duty was the factual and legal cause of plaintiffs
injury, and that plaintiff suffered actual loss or damage as a result. 166 Defendant
may be the subject of a higher duty of care if the defendant holds himself out as
167
possessing special skills and training.
In a series of professional publications and presentations, Cem Kaner has
168
convincingly documented the applicability of negligence law to computer software.
Software programmers are under a duty to create products that do not create an
unreasonable risk of injury or property damage, and to provide services of a quality
that would be provided by a reasonable member of the software programming
industry. 169
Mr. Kaner has identified several causes of action for software
negligence, including negligent pre-sale misrepresentation, negligent programming,
negligent software testing, negligent software quality control planning, professional
170
negligence, and negligent post-sale misrepresentation.
Today's international technology economy depends on the supply of human
creativity from the following three sources: designers and developers who design,
manufacture, and distribute technology products; designers and developers who
license their designs to others to refine, manufacture, and distribute; and
independent designers who apply their professional skills to create technological
171
designs for products that satisfy market needs.
163 Id. at
164

34.
Id. at 28.

165 Id. at 30.
'66 RESTATEMENT (SECOND) OF TORTS

§

281 (1979).

Kaner, supra note 162, at 22.
168 See e.g., Cem Kaner, The New Legal Regime, Bad Software and a Place for Certification,
available athttp://www.kaner.com/pdfs/slides/lawcert.pdf (last visited April 15, 2003).
169 See Kaner, supra note 162, at 194-95.
170 Id. at 193-252.
171 See generally Melissa Evans Buss, Products Liability and Intellectual Property Licensors,
107

27 WM. MITCHELL L. REV. 299 (2000).
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As applied to the three sources of technology design, PreMarket Submissions,
Off the Shelf Software, and Software Validation combine to create a composite
standard similar to those used to regulate the practice of the learned professions.
Just as a trial lawyer must know the rules of evidence and appellate procedure, a
medical device software engineer must know and practice the rules of software risk
analysis and statement coverage. Just as an orthopedic surgeon must know the
anatomy of the human skeletal system and current surgical practice, a medical
software engineer must know and practice the rules of software risk and statement
coverage.
As such, injured persons, as individuals or as members of a class, can now be
expected to use the courts to demand that medical device software venturers, medical
device manufacturers and distributors, and medical software intellectual property
holders lawfully discharge their duty to architect, develop, document, distribute and
172
maintain safe and efficacious medical software.
The time is at hand when the courts will demand that the general practice of
software engineering conform its conduct to the level of conduct practiced by the
medical software industry; this particularly presents a special concern to the general
commercial software industry. The law in that regard is clear. The courts impose a
legal duty of care in the absence of reasonable conduct on the part of industry;
liability for breach of a duty of care will be imposed where the burden of prevention is
173
less than the probability of an accident and the gravity of the resulting harm.
The social demand for secure, private, safe and effective software ensures that
the new federal regulatory medical software standard will inexorably migrate to the
general commercial software industry. The general commercial software industry
will soon be subject to much broader liability then it is now accustomed to. It is only
a matter of time.

2. Software Programsand the Law ofProductsLiability
For the past forty years, American medical device law has been guided by
Section 402A of the Restatement (Second) of Torts. 174 The underlying premise of the
172 Contra Jonathan K. Gable, An Overview of the Legal Liablities FacingManufacturers of
Medical Information Systems, 5 QUINNIPIAC HEALTH L.J. 127, 143 (2001). "The likelihood that a

simple negligence claim would succeed is very slim given a consistent refusal by the courts to hold
software providers to the higher duty of care." Id.; W. Robert Collins, How Good is Enough?An
Ethical Analysis of Software Construction and Use, Communications of the Association for
Computing Machinery, (Jan. 1994); Cem Kaner, The Law ofSoftware Quality, 248 (1999).
173 United States v. Carroll Towing, 132 F.2d 170 (2d Cir. 1947) (Hand, J.). Courts will impose
liability for breach of a duty of care where the burden of prevention is less than the probability of an
accident times the gravity of the resulting harm. Id. at 173; The T. J. Hooper, 60 F.2d 737 (2d Cir.
1932) (Hand, J.). "There are, no doubt, cases where courts seem to make the general practice of the
calling the standard of proper diligence. Hooper, 60 F.2d at 740. "Indeed in most cases reasonable
prudence is in fact common prudence; but strictly it is never its measure; a whole calling may have
unduly lagged in the adoption of new and available devices." Id. "[T]here are precautions so
imperative that even their universal disregard will not excuse their omission." Id.
174 RESTATEMENT (SECOND) OF TORTS
§ 402A (1965); see Michael J. Wagner & Laura L.

Peterson, The New Restatement (Third) of Torts - Shelter from the Product Liabilty Storm for
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Restatement, as adopted by the vast majority of American courts and state
legislatures, is that the manufacturer or seller of a defective product that is
unreasonably dangerous to the user or consumer is liable for physical harm caused
175
by the product.
The Restatement (Second) devoted almost no coverage to the treatment of the
liability for prescription drugs and medical devices. The only relevant insights
appear in the infamous "comment k":
Unavoidably unsafe produets. There are some products, which, in
the present state of human knowledge, are quite incapable of being
made safe for their intended and ordinary use. These are especially
common in the field of drugs. An outstanding example is the vaccine
for the Pasteur treatment of rabies, which not uncommonly leads to
very serious and damaging consequences when it is injected. Since
the disease invariably leads to a dreadful death, both the marketing
and use of the vaccine are fully justified, notwithstanding the
unavoidable high degree of risk, which they involve. Such a product,
properly prepared and accompanied by proper directions and
176
warning, is not defective nor is it unreasonably dangerous.
"Comment k" prompted the American courts and state legislatures to adopt
inconsistent and contradictory products liability laws. 177 Among other things,
"comment k" has prompted the courts to consider whether the court or the jury
should weigh risks and benefits to determine whether a product falls within the
reach of "comment k" coverage. 178 Citing "comment k" for guidance, leading state
courts have reached differing positions on identical issues. The California Supreme
Court recently announced a rule imposing strict liability on manufacturers for the
failure to disclose known or knowable risks. 179 In contrast, the Washington Supreme
Court held that manufacturers could be held liable only for their negligent failure to
180
disclose known or knowable risks.
It is unlikely that a reviewing court would consider "comment k" to constitute
useful guidance for the resolution of a medical device software tort action. "Comment
k" was included in Restatement (Second) 402(A) as an exception to the rule of strict
liability for products, like the rabies vaccine, that are by necessity of design or
intended use, "unavoidably unsafe" yet highly beneficial to society. The new FDA
regulations for the architecture, development, and maintenance of medical software
would almost surely prohibit a grant of conditional FDA approval for the marketing
PharmaceuticalCompanies and Medical Device Manufacturers?, 53 FOOD DRUG & COSM. L.J. 225,
226 (1998).
175 See generallyWagner & Peterson, supra note 174, at 226-27.
176 RESTATEMENT (SECOND) OF TORTS,

§

402A cmt. k (1965).

177 See Wagner & Peterson, supra note 174, at 231 (ongoing debate between courts, law review
commentators, and even the comment's reporters exists due to the ambiguous language contained
within "comment k").
178 Id.
17) Carlin v. Superior Court, 920 P.2d 1347 (Cal. 1996).
180 Young v. Key Pharms., Inc., 922 P.2d 59 (Wash. 1996).
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of medical software programs that by design were known to be unsafe and could not
be rendered safe within the FDA guidance structure.
Technology designers have, in fact, been named as defendants in products
liability lawsuits. 1 8 1

The case law generally holds that the technology designer who

remains involved in the manufacture and distribution of a defective product, and the
independent technology designer whose design is later used to manufacture and
distribute the defective product, can be held liable in products liability to third
parties whose injuries are caused by the designer's negligence.18 2 The technology
designer who does not "substantially participate" in the design of the marketed
product is excused from liability. "Substantial participation" is determined on the
18 3
particular facts of the case.
Computer software standards organizations, commentators and attorneys have
suggested a variety of definitions to be used to characterize software "defects" that
would render a software program a "defective product" within the meaning of Section
402(A):
Defect: A product anomaly. Examples include such things as (1)
omissions and imperfections found during early life cycle phases and
(2) faults contained in software sufficiently mature for test or
18 4
operation.
Anomaly: Any condition that deviates from expectations based on
requirements specifications, design documents, user documents,
standards, or from someone's perceptions or experiences. Anomalies
may be found during, but not limited to, the review, test, analysis,
compilation, or use of software
products or applicable
documentation. 185
Software defects can be divided into four broad categories: (1) requirements
defects, (2) design defects, (3) code defects, and (4) documentation defects.18 6 There is
a group of software nonconformities that represent serious threats to the welfare of
users and bystanders. These nonconformities are called defects, and they not only
can cause injury but may also result in the manufacturers, designers, or sellers being
sued under the product liability laws. There is also a class of defects called design
defects, which can be responsible for customer dissatisfaction, loss, injury or death.187

181 See Buss, supranote 171, at 311-14.
182

Id. at 311.

183 Id.
'8
ANSI/IEEE STANDARD 982.1, IEEE STANDARD DICTIONARY OF MEASURES TO PRODUCE
RELIABLE SOFTWARE, INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, p. 13 (1988).
185 Id. at 3.
186 See WILLIAM H. ROETZHEIM, DEVELOPING SOFTWARE TO GOVERNMENT STANDARDS 6-7

(Prentice-Hall 1991).
187 General Motors v. Johnston, 592 So.2d 1054 (Ala. 1992). Programmable Read Only Memory
chip containing modified software controlling the fuel injector in Chevrolet truck may have caused
"rolling, hunting or surging idles" that were cause of plaintiffs injuries. Id.
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The issue becomes more important in the context of the clear trend of
international commerce to integrate or to imbed software into goods and human
beings.18 8 Moreover, successive applications, refinements and enhancements of
technologies often render indistinguishable the original labels used to distinguish the
technologies as "computers," "chips," "hardware," or "software." 18 9 The same holds
true for the types and forms of intellectual properties that are integrated or
190
imbedded into software.
Section 6 of the new Restatement (Third) of Torts: Products Liability, is being
considered as a source of guidance for the courts.191 The Restatement (Third)
1 92
includes special provisions applicable to prescription drugs and medical devices.
Section 6(c) of the Restatement (Third)states:
A prescription drug or medical device is not reasonably safe due to
defective design if the foreseeable risks of harm posed by the drug or
medical device are sufficiently great in relation to its foreseeable
therapeutic benefits that reasonable health care providers, knowing
of such foreseeable risks and therapeutic benefits, would not
1 93
prescribe the drug or medical device for any class of patients.
The suggested Restatement (Third) standards present a series of startling
changes to the generally accepted legal standards used to evaluate drug and device
liability in products liability actions. The suggested standard would limit liability to
only those medical devices that provide no benefits to any identifiable class of
patients. 194 The suggested standard would shift the burden of knowledge concerning
the performance of medical device products from manufacturers to the prescribing
physicians.1 95 In some states, the suggested standards would shift the burden of
proof that a medical device is not reasonably safe to the plaintiff.1 96 As such, the
suggested standards are open to serious challenges.

188 See generally Steven Kotler, Vision Quest: A Half-Century of Artificial Sight Research as
Succeeded. And Now This Blind Man Can See, WIRED, (Sept. 2002) (asking what liability for
technology designers and manufacturers who mass market new bio-engineered products that are
implanted in the human brain).
189 See Cem Kaner & David Pels, Report to the Federal Trade Commission, In the Matter of
High Technology WarrantyProject,FTC File No. P994413 (Sept. 11, 2000).
190 Buss, supra note 171, at 311-14 (providing an analysis of Aim v. Aluminum Co. ofAmerica,
717 S.W.2d 588 (Tex. 1986), MechanicalRubber & Supply Co. v. CaterpillarTractor Co., 399 N.E.2d
722 (Ill. App. Ct. 1980), and La Rossa v. Scientific Design Co., 402 F.2d 937 (3d Cir. 1968)).
191 See Buss, supranote 171, at 280.
192 RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY (1998); see generally Wagner &
Peterson, supra note 174, at 228-29; Harvey L. Kaplan, et al., ThirdRestatement: New Prescription
for Makers of Drugs and Medica] Devices: Third Restatement of Torts Draft, 61 DEF. COUNS. J. 64
(1994).

193 RESTATEMENT (THIRD) OF TORTS § 6 (1998).

191See Wagner & Peterson, supra note 174, at 233 (citing RESTATEMENT (THIRD) OF TORTS:
PRODUCTS LIABILITY § 6, cmt. f, reporters' note).
195 Id. at 234.
196 Id. at 235.
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The suggested standards fail to properly distinguish between drugs and devices
and make no mention of medical device software. The underlying scientific premise
supporting the development of medical software is that human tissue, compounds,
and molecules are nearly identical throughout the species. Unlike prescription
drugs, medical software devices of the type described here are intended to gather,
filter, and analyze data on a consistent, repetitive, scientifically accurate basis.
Thus, the ingestion of a pharmaceutical compound should not be legally equated with
the use of an electronic algorithm to analyze the depiction of interaction of energy
waves with human tissue, compounds and molecules.
The reality of professional medical practice is that with respect to the use of
medical software and medical devices using integrated or embedded medical
software, a treating physician has no other choice but to rely on manufacturer
representations. Physicians cannot be expected to possess the scientific training
necessary to comprehend the entirety of the design and manufacture of a medical
device software technology. Only the medical software technology designers and
manufacturers are positioned to know the capacities and operational tendencies of
their equipment.
The suggested standard is squarely at odds with the intent of the FDA
regulatory scheme. Manufacturers of medical device products must demonstrate, or
"validate" in the case of medical software, that the medical devices they intend to
market are safe and efficacious before the FDA will grant conditional approval of
devices for market use.
Although the suggested standard supports the use of a "reason based
alternative-design approach," the standard does not provide for the application of
strict products liability doctrine followed in many American states. In view of the
fact that mass torts may result from the use of widely distributed, intensely marketfocused, defective medical device software, the "reason based alternative-design
approach" may afford defendants a proof advantage that their actions do not
warrant. For example, should classes of persons whose "individually identifiable
health information" is lost, stolen, scrambled, or corrupted be required to prove the
negligence of each of the medical software components involved? I think not.
Further, the suggested standard makes no allowance for the likelihood that
injuries arising from the use of medical software may be found to be the result of the
interaction of two or more faulty software programs. In that instance, general
negligence law would allow the injured plaintiff to hale in both of the injury causing
software product manufacturer-distributors to prove his injury, and then require the
defendant, software product manufacturer-distributors, to prove that their individual
negligence was not the cause of the plaintiffs injury.
Finally, the Article 6(c) standard seems to be based on the theory that licensed,
practicing medical professionals would prescribe the use of a medical device knowing
that the device supplied no medical benefit to any class of identifiable class of
patients. The standard seems to embody the principles of quackery, the antithesis of
professional medical practice, as the baseline point for the imposition of liability.
Thus, the only rationale that can be offered for the suggested changes is that
they were drafted to attempt to insulate drug and device manufacturers from
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liability. 197 On balance, with respect to resolution of disputes and the allocation of
liability involving harm caused by the use of medical device software, I believe a
reviewing court will likely reject the Article 6(c) suggested standards. Thus, business
models and operational strategies premised on the supposed grant of limitation of
liability offered by Article 6(c) standards are faulty.
Whether the courts will accept Restatement (Third) guidance for medical device
products in general, and for medical device software in particular, is an open
question. The record thus far is mixed. Several states have openly repudiated the
Restatement (Third).198 In view of the utter reliance a patient places on the quality of
care he will receive at the hands of his physician, the suggested Restatement (Third)
guidance for medical devices that integrate or imbed medical device software is
incorrect. The standards of our time and the time to come demand far more than the
Restatement (Third)provides.

B. Tort Law Preemptionof FDA Regulation
For some years, it was common practice to assume that federal FDA pre-market
approval preempted common law causes of action, thus immunizing FDA-approved
medical devices against state common law liability. 199 In that same vein, the
Restatement (Third) mildly advocates federal preemption of common law causes of
200
action with respect to warnings affixed to drugs and medical devices.
The Supreme Court addressed this issue in Medtronic v. Lohr.20

1

Justice

Stevens rejected Medtronic's position that the Medical Device Amendments Act of
1976 preempted common law claims against manufacturers for damages caused by
medical devices. Justice Stevens reasoned that the general common law duties to use
due care in manufacturing and to warn users of potential risks posed no threat to
federal requirements, and such duties were not the type of requirements that impede
20 2
the ability of the FDA to enforce specific federal laws and regulations.
197 Id.

at 242.

198 Carlin v. Superior Court, 920 P.2d 1347 (Cal. 1996); Wagner & Peterson, supra note 174, at

240.
199 See generally Green & Shultz, supra note 16, at 2123-28 (analyzing the merits of a FDA

pre-emption defense); Lars Noah, Rewarding Regulatory Compliance: The Pursuitof Symmetry in
Products Liability, 88 GEO. L.J. 2147 (2000); Richard B. Stewart, Regulatory Compliance Preclusion
of Tort Liability: Limiting the DualTrack System, 88 GEO. L.J. 2167 (2000); Rachel Tumidolsky,

How Medtronic v. Lohr Has Redefined Medical Device Regulation and Litigation, 65 DEF. COUNS.

J. 268, 269-76 (1998).
200 RESTATEMENT (THIRD) OF TORTS § 6, cmt. b (1998).

The rules imposing liability on a manufacturer for inadequate warning or
defective design of prescription drugs and medical devices assume that the federal
regulatory standard has not preempted the imposition of tort liability under state
law.
Where such preemption is found, liability cannot attach when the
manufacturer has complied with the applicable federal standard.
Id.

201 Medtronic

v. Lohr, 518 U.S. 470 (1996).

202 Id. at 501-02; see also Tumildosky, supra note 199, at 271 (discussing how FDA-imposed
requirements preempt state common law duties when the FDA has expressly imposed, by regulation
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By way of example, the recent holding of the United States District Court for the
District of Virginia in Woods v. G(iatech,Inc.,20 3 follows the line of cases interpreting
the Medtronic rule. Defendant Gliatech developed, tested, distributed and marketed
ADCON-L, a Class III gel product used to inhibit post-surgical growth of scar tissue.
Gliatech failed to notify the FDA that surgeons were reporting adverse medical
reactions in surgical patients treated with the gel. 20 4 Relying on the information
submitted by Gliatech, the FDA granted conditional approval for the marketing of
ADCON-L. 205 The court ruled that the FDA's conditional pre-market approval of the
gel, and the FDA's accompanying findings regarding the gel's safety and
20 6
effectiveness, did not create a specific federal requirement triggering preemption.
The court thus allowed plaintiff to proceed with common law claims of negligence and
breach of warranty arising from injuries suffered as a result of the medical use of
207
defendant's gel.

1.

Tort Law and the Uniform Computer Information TransactionsAct

The new UCITA warranty provisions have the effect of limiting or denying
altogether the ability of third parties to recover for a breach of a UCITA warranty.
The Reporter's Notes make it clear that the UCITA warranty provisions were drafted
so as to minimize the reach of tort law:
Third Parties. This section deals with express warranties made by
the licensor to its licensee. It does not deal with the enforceability
under contract or tort theory of representations made by remote
parties and relied on by an ultimate user of information. Cases in
tort dealing with such issues pertaining to information does not
generally parallel cases dealing with the manufacture and sale of
goods. Information providers have been held liable to third parties in
only a few, atypical cases. This Act does not establish, expand or
208
exclude such third party liability.
RHelationship to Tort Law. Since this section creates a new warranty
analogous to the theory of negligent misrepresentation, disclaimer or

or order, a specific substantive requirement applicable to a particular medical device and state
common law imposes a substantive requirement applicable to the same particular medical device
that is different from or in addition to, any requirement applicable to the FDA requirement); 21
C.F.R. § 808 (1996); see also Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341, 347-48
(2001) (explaining that state law causes of action based solely on fraudulent misrepresentations
made to the FDA to obtain market approval are impliedly preempted).
203 218 F. Supp. 2d 802 (W.D. Va. 2002).
201 Id. at 803.
205 Id. at 803-04.
206Id. at 808.
207 Id.; see also Surgical Get FederalLaw Does Not Bar Claims Against Maker of Faulty Gel
Product,PRODUCT LIABILITY DAILY (September. 12, 2002).
208U.C.I.T.A., § 402, Reporters' Note § 9 (2001) (Draft).
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non-existence of the implied warranty should have a bearing on
existence of the tort claim in the same transaction. In cases of
economic loss, a disclaimer of this warranty in most cases forecloses
a tort claim based on the same facts. However, this section does not
foreclose development of other approaches under tort law ....
This
Act neither precludes nor encourages further exploration of the tort
20 9
law questions.
Products Liability Law This section does not deal with products
liability issues. It neither expands nor restricts tort concepts that
might apply for third party risk, leaving development or nondevelopment of any appropriate liability doctrine to common law
courts. Indeed, few courts impose third-party tort liability in
transactions involving information. The Restatement (Third) on
Products Liability, recognizing this, notes that informational content
is not a product for that law. . . . While there may be a different
policy for software embedded in tangible products, this Act does not
deal with embedded software.
Contract issues regarding such
software, such as the computer program that operates the brakes in
an automobile sold to a consumer, are within the Uniform
210
Commercial Code.
The purpose of medical device software is to provide accurate and reliable
information that can be used to diagnose and treat human illness. The efforts taken
by the drafters of UCITA to distance UCITA from the host of issues that arise from
transactions in medical information in general, and individually identifiable health
information in particular, should be changed to reflect the practical reality unfolding
in the American medical profession. The UCITA warranty provisions should be
drafted to affirmatively state that liability in tort may exist for negligently drawn,
developed, distributed, and maintained medical device software.

2. New MedicalSoftware Torts
The FDA and HHS regulatory frameworks will combine to impose legal duties
that regulate the creation, storage, and transmission of digital, individually
identifiable health information. Inevitably, patients will be injured by the improper
distribution, loss, alteration, or corruption of their personal data.
Injured patients can be expected to capitalize on the legal duties created by the
FDA scheme and the proposed HHS regulatory schemes to impose tort liability on
medical software designers, businesses that market medical software, businesses
that market medical devices that integrate or imbed medical software, and holders of
medical software intellectual property rights that cause injury.

20)
210

U.C.I.T.A., § 6 (2001).
U.C.I.T.A. § 409, Reporters' Note § 3 (2001).
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a. Privacy Tort: The Unlawful Use of IndividuallyIdentifiableHealth
Informa tion
The unlawful use of "individual health information" is a federal felony. 211 The
"knowing misuse" of "individually identifiable health information" carries a fine of
not more than $100,000 and imprisonment of not more than five years or both. The
"misuse" of "individually identifiable health information" with intent to sell, transfer,
or use of individually identifiable health information for commercial advantage,
personal gain, or malicious harm carries a fine of not more than $250,000 and
212
imprisonment of not more than 10 years or both.
Pursuant to the well-established doctrine of negligence per se, a precise
standard of care in a tort action may be established by proof of the applicability to
the case of a statute providing for criminal penalties. When such proof is shown, the
specific statutory duty imposed by the criminal statute replaces the general common
law duty of care.
Proof of negligence per se requires the plaintiff to prove that he is in the class of
persons protected by the criminal statute, that the statute was intended to prevent
the type of harm that he suffered, and that the statute clearly proscribes the actions
of the defendant. Breach of the duty imposed by a criminal statute is prima facie
evidence of negligence to be considered by the trier of fact.
This new tort is a cousin to the existing common law tort of public disclosure of
private facts.
The rationale for the common law tort rests in the wrongful
publication or public disclosure by the defendant of private information about the
plaintiff that a reasonable person of ordinary sensibilities would object to having
been made public.

b. Security Tort: The Negligent Disclosure,Alternation or Loss of Individually
IdentifiableHealth Information
The excerpts that follow below appear as portions of the "Proposed Rule for
Security and Electronic Signature Standards" published by the Health Care
Financing Administration of the HHS.2 13 Final rules are expected near term. The
structure of the Proposed Rule strongly suggests that HHS will follow the regulatory
example set by FDA. Thus, the final HHS regulations will likely establish a broad
composite standard that can be used as a statutory standard of care regulating the
2 14
electronic exchange of "individually identifiable health information":

211
212

Security and Electronic Signature Standards, 45 C.F.R. § 142 (2002).
Id.

213 See

id.

2H 45 C.F.R. § 142 (2002).

Portions of the proposed rule became effective in October 2002 for
health care clearinghouses and health care provider that chooses to transmit any of the transactions
in electronic form, and will become effective in October 2003 for small health care plans. Id. See
U.S. DEP'T OF HEALTH AND HUMAN RESOURCES, Frequently Asked Questions About Electronic

Transaction

Standards

Adopted

Under

HIPAA,

available

at

http://asppe.hhs.gov/adminsimp/faqtx.htm (last visited April 14, 2003); U.S. DEP'T OF HEALTH AND

[2:259 2003]

The Next Wave

There is no recognized single standard that integrates all the
components of security (administrative procedures, physical
safeguards, technical security services, and technical mechanisms)
that must be in place to preserve health information confidentiality
and privacy as defined in the law. Therefore we are designating a
new, comprehensive standard, which defines the security
requirements to be fulfilled....
In fact, there are numerous security guidelines and standards in
existence today, focusing on the different techniques available for
implementing the various aspects of security. We thoroughly
researched the existing guidelines and standards and consulted
extensively with the organizations that developed them....
The standard does not address the extent to which a particular
entity should implement the specific features. Instead, we would
require that each affected entity assess its own security needs and
risks and devise, implement, and maintain appropriate security to
address its business requirements.
How individual security
requirements would be satisfied and which technology to use would
be business decisions each organization would have to make....
The recommendations contained in the National Research Council's 1997
report For The Record: Protecting Electronic Health Information support
our approach to the development of a security standard ....
The report
concludes that appropriate security practices are highly dependent on
individual circumstances, but goes on to suggest that [i]t is therefore not
possible to prescribe in detail specific practices for all organizations; rather,
each organization must analyze its systems, vulnerabilities and risks, and
resources to determine optimal security measures.
Nevertheless, the
committee believes that a set of practices can be articulated in a sufficiently
general way that they can be adopted by all health care organizations in
one form or another ....
Inherent in this approach is a balance between the
need to secure health data against risk and the economic cost of doing so.
Health care entities must consider both aspects in devising their security.
The proposed security standard addresses the following policies, practices, and
procedures:
Technical Practices and Procedures
1. Individual authentication of users

HUMAN RESOURCES, What are the major differences between the proposed rule and the final rule?,

available athttp://asppe.hhs.gov/adminsimp/faqtx.htm (last visited April 14, 2003).
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2.
3.
4.
5.
6.
7.
8.

Access controls
Audit trails
Physical security and disaster recovery
Protection of remote access points
Protection of external electronic communications
Software discipline, and
System assessment.

Technical Security Services to Guard Data Integrity, Confidentiality and
Availability
1.
2.
3.
4.
5.

Access Control
Audit Control
Authorization Control
Data Authentication
215
Entity Authentication.

Persons injured by the negligent disclosure, loss, or alteration of personal,
individually identifiable health information can be expected to look for recovery from
all persons or entities who had access to, or were involved in, the electronic
transmission of personal medical information.
In the absence of statutory change, the liability of physicians and their agents
for the negligent disclosure, loss, or alteration of digital individually identifiable
health information will be determined using the laws of professional negligence. The
liability of digital intermediaries for the negligent disclosure, loss, or alteration of
personal, individually identifiable health information will be governed by the Digital
Millennium Copyright Act. 216 The liability of medical software designers, businesses
that market medical software, and medical software intellectual property rights
holders will be determined using the FDA and HHS regulatory standards. Under
either or both of the FDA or HHS regulatory standards, liability in tort for the
negligent disclosure, alternation or loss of individually identifiable health
information is here to stay.

VI. COUNSELING THE MEDICAL SOFTWARE VENTURE
The development of a business model for a medical software venture is a very
complex, iterative task. The sophistication of the technology, the fact that medical
software may be associated with, integrated into, or imbedded into medical devices,
and the nature of the various intellectual property rights involved, present an
unusually complex planning task requiring the application of sophisticated business
215

45 C.F.R. § 142 (2003).

17 U.S.C. § 512 (2002). Sections 512(a) and (c) provide "safe harbor" exemptions for passive
carriers and for system storage activities at the direction of the user. Id.; see also Religious Tech.
Ctr. v. Netcom On-Line Communication Servs., Inc., 907 F. Supp. 1361 (N.D. Cal. 1995); A & M
Records, Inc. v. Napster Inc., 54 U.S.P.Q.2d 1746 (N.D. Cal. 2000).
216
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judgment and legal advice. Reasonable prudence requires in-depth thought and
considered action.
The business strategy of the medical software venture serves as the base point
for analysis. How do the principals of the venture intend to market the medical
software? Do they intend to form their own marketing and manufacturing operations
for the software and the medical devices that use the software? Do they intend to
market the medical software through a cross-licensing agreement with a strategic
partner? Do they intend to license the medical software to a major medical device
manufacturer? Do they intend to sell the medical software to the highest bidder?
Unlike most new software products in the software industry, medical device
software will likely have a lengthy commercial life. It will probably be easier to
design products around medical device software than it will be to rewrite the
software itself. Medical software ventures will wish to avoid the cost of repetitive
encounters with the FDA "validation" process: they will be averse to subjecting their
sophisticated, FDA-approved, field-tested code to rapid revision.
The mix of types of intellectual property available for the protection of medical
software is especially complex. In view of the fact that medical software can be
integrated with or imbedded in other medical devices, careful attention must be paid
to the choices of types of property rights sought. The principals of the venture must
understand how the complex mix of intellectual property software can be used to
attain their business objectives.
Patent and copyright protection can be used to protect different segments of a
software program. 217 The copyright symbol may be placed on drawings illustrating a
patent application. 218 The General Counsel to the Copyright Office has determined
219
that patent law and copyright law protection may co-exist in computer programs.
Patent and trade secret protection in software programs are typically mutually
exclusive. 220 To obtain software patent protection, the applicant must disclose
related trade secret data necessary to allow one skilled in the software art to practice
the learning that is disclosed in the patent. 221 However, an innovative software
subroutine at the heart of the program can be protected by patent while the main
222
body of the program remains a trade secret.
223
Copyright and trade secret protection may co-exist in a software program.
The Code of Federal Regulations contains provisions stating that software being
submitted for copyright registration may contain redacted trade secret information if
the remainder contains "an appreciable amount of original computer code. 224
Computer programs may simultaneously contain literary works protected by the
217

See Judith Szepesi, Maximizing Protection for Computer Software, 12 SANTA CLARA

COMPUTER & HIGH TECH. L.J. 173, 194-95 (1996).
218MANUAL OF PATENT EXAMINING PROCEDURES, § 608.01(v) (1995).
219 Contra Michael Kline, Requiring an Election of Protection for Patentable/Copyrightable
Computer Programs,6 COMPUTER/L.J. 607, 638-75 (1986); David A. Einhorn, Copyright and Patent
Protectionfor Computer Software;Are They Mutually Exelusive?, 30 IDEA 265, 274-75 (1990).
220 Szepesi, supranote 217, at 195.
221 White Consol. Indus. v. Vega Servo Control, Inc., 713 F.2d 788 (Fed. Cir. 1983).
222Id.
223 Szepesi, supranote 217, at 196.
224 37 C.F.R. § 202.20(vii)(A)(2) (2002).
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federal copyright law, as well as processes and software programs protected under
trade secret law.22 5 Although copyright law allows "fair use" decompiling of a
program to obtain program information that is non-copyrightable, 226 decompiled
program language may retain trade secret protection if the code is the subject of a
227
license agreement between the parties that prohibits reverse engineering.
The cost of obtaining and maintaining protection for intellectual property rights
in medical device software must be factored into the strategic business model.
Patent prosecutions, intellectual property landscape surveys, and validity/noninfringement opinion letters of counsel can easily cost many tens of thousands of
dollars.
Maintaining a vigorous, effective in-house trade secret program is an
expensive necessity.
Medical device software litigation is a certainty. The prosecution or defense of a
software patent infringement suit can be expected to cost a minimum of $1,000,000
per party; the prosecution or defense of a copyright or trade secret infringement
action can be expected to cost a minimum of $250,000 per party. New forms of
intellectual property insurance coverage are being marketed to insure against the
costs of intellectual property rights suits brought against technology ventures. Even
so, it may become strategically necessary for the venture to fund critical intellectual
228
property rights using the venture's precious cash resources.

VII. PROPOSED GUIDELINES
With all of the above considered, I offer these summary guidelines:
1. A medical software venture must vigilantly strive to understand what
intellectual property it has created and owns, as well as what intellectual property it
has not created and does not own. All information and data created by the venture is
probably the subject of one or more forms of intellectual property law; each of which,
should be recognized, protected, and exploited. All information and data that has not
225 Comprehensive Techs. Int'l, Inc. v.
226 Sega Enters. Ltd. v. Accolade, Inc.,

Software Artisans, Inc., 3 F.3d 730 (4th Cir. 1993).
977 F.2d 1510, n.7 (9th Cir. 1992).
227 See generallySzepsis, supranote 217, at 197-203.
228 See Chubb Launches Now "Sealable'Errors
& Omissions Insurancefor Hi-h -Tech Industry,
SPEECH

TECHNOLOGY

MAGAZINE,

AMCOMM

HOLDINGS

(July

23,

2002),

available

at

www.speechtechmag.com/pub/industry/971-1.html.
Several major insurance companies now offer
technology risk insurance. Id. American International Companies market the AIG eBusiness Risk
Solutions family of policies that insure risks associated with establishing an Internet business,
delivering professional services via the Internet, or conducting e-commerce. Id. The AIG net
Advantage Complete insurance policy provides up to $25,000,000 liability insurance coverage for
risks of loss arising from Web Content Liability, Professional Errors and Omissions, Network
Security Liability, Cyber Extortion, Network Security Loss (1st Party Intangible/Information),
Network Security Business Interruption Coverage (1st Party), a Cyber Criminal Reward Fund, and
a Crisis Communication Management Fund. www.aignetadvantage.com. Id. The Chubb Group of
Insurance Companies recently announced it will offer scalable coverage for information and network
technology companies. Id. The Chubb INTegrity policy will insure against the risks of loss
associated with contractual Definitions of Loss, Final Acceptance Criteria, Privacy Violations,
Intellectual Property Infringement, and Security Breach by Others. Id.
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been created by the venture must be considered the intellectual property of others.
The non-lawful use of the intellectual property of others invites "bet-the-business"
litigation. Certain industry practices in vogue, "data-mining" in particular, are
intellectual property liability traps for the unwary.
2. The medical software venture must operate a rigorous intellectual property
recognition and protection program. All documents and data related to the medical
software should be treated as if they were trade secrets. Hard copies should be
strictly accounted for and physically safeguarded, and electronic documents and
databases should be physically guarded, encrypted, and subject to password
protection. All software-related information and data created by the venture, in both
hard copy and electronic versions, should be regularly screened and classified for the
type of intellectual property protection needed. Information or data deserving trade
secrets should be given scaled levels of protection. Trade secret data should be
segregated into data to be made available to third parties only upon receipt of an
executed non-disclosure agreement, with such data effectively being made available
on a "need-to-know basis." The venture should conduct a semi-annual marketing
survey to attempt to determine whether competitors may be using portions of the
medical device software, thereby encroaching on the venture's precious intellectual
property rights. Key employees of the venture and all persons having access to the
software code must execute written contracts containing non-disclosure terms and
non-compete agreements, to the extent allowed by state law.
The venture's
scientists, engineers, and researchers should be regularly interviewed to determine
what portions of their work they believe are valuable new intellectual property. In
all instances, the venture should aggressively protect and defend its intellectual
property rights.
3. The medical software venture should seek copyright protection for the
medical device software. Copyright protection provides an additional measure or
protection for abstract and creative content. Copyright protection extends for a
longer term. Copyright protection begins at the time the software algorithm is placed
on a tangible medium.
4. The venture must determine whether it will seek patent protection for the
medical software. Despite its higher cost, patent protection might provide a host of
business advantages and benefits. Patent protection for medical software would
allow the software to be more widely distributed in the broader market. Patent
protection for the medical software could serve as the anchor for a portfolio of related
intellectual properties. Prospective purchasers or licensees of the code and the
venture will be more likely to act knowing the code was the subject of a grant of a
valid patent. The pre-requisite "Freedom to Practice/Non-Infringement" letter from
intellectual property counsel can be used as baseline to monitor the actions of
competitors.
5.
The FDA medical software validation process must be very carefully
structured and managed. An "FDA Approval Committee," comprised of the chief
executive, the chief technologist, the chief medical expert, and general counsel,
should be appointed to serve for the life of the FDA approval process. The committee
should review each document to be submitted to the FDA for the presence of nonexcised trade secret information. Each document to be submitted to the FDA should
be individually numbered and indexed. Any document that must be submitted to the
FDA that cannot be "scrubbed" to remove or disguise trade secret information should
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carry the following legend: "This document contains Trade Secret data proprietary to
(the name of the venture). Federal law prohibits disclosure of this document or data
contained in the document to anyone other than FDA personnel or third-party
certification personnel. 21 CFR 20.61"
6. Respecting day-to-day operational concerns, the medical software venture
must thrive on an inter-related set of strategic policies. Agreements governing the
efforts to create, license, lease, or assign medical software must be the subject of
negotiation and review by competent counsel.
The venture must maintain a
comprehensive portfolio of products liability, errors, omissions, and intellectual
property insurance coverage. The venture should also dedicate of a portion of its
revenues to fund its intellectual property recognition, protection, and enforcement
program. The venture should retain litigation counsel on a standby basis.

CONCLUSION
The lawyer in the rich, demanding, rapidly changing medical device software
business environment needs to do more than appreciate the strategic importance of a
diverse set of laws and circumstances relevant to his or her client's interests. Your
clients are treading in the outer boundaries of technology, business, and law. Your
task is to ground their optimism, will, purpose, and extraordinary competence with
your knowledge of the risks and opportunities presented to them.

